^
13h
Insulin-like growth factor-1 as predictive factor of difficult laryngoscopy in patients with GH-producing pituitary adenoma: A pilot study. (PubMed, J Clin Neurosci)
Higher IGF-1 levels correlate with the probability of having a higher Cormack-Lehane score; classical bedside scores, such as mLEMON and EGRI, were not able to predict difficult laryngoscopy in our population.
Clinical • Journal
|
IGF1 (Insulin-like growth factor 1)
13h
Pheochromocytoma due to a novel SDHD variant presenting as unilateral visual loss. (PubMed, Endocrinol Diabetes Metab Case Rep)
Novel variants are commonly uncovered in the Succinate Dehydrogenase (SDH) subunit; proving pathogenicity is a complex, time-consuming process and one challenge of next-generation sequencing (3). SDHB immunohistochemistry as a tool for demonstrating pathogenicity is associated with reduced sensitivity when assessing SDHD variants (5, 6).
Journal
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHD (Succinate Dehydrogenase Complex Subunit D)
14h
Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome. (PubMed, Front Vet Sci)
Additionally, miR-141-3p was expressed significantly lower (p = 0.009) in dogs with csACTs that had a histopathological Utrecht score of ≥ 11 compared to those with a score of <11. These results indicate that circulating miRNAs have the potential to be non-invasive biomarkers in dogs with Cushing's syndrome that may contribute to clinical decision making.
Journal
|
MIR126 (MicroRNA 126) • MIR141 (MicroRNA 141) • MIR223 (MicroRNA 223) • MIR375 (MicroRNA 375) • MIR122 (MicroRNA 122) • MIR483 (MicroRNA 483)
|
miR-141 expression
15h
Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort. (PubMed, Clin Endocrinol (Oxf))
Somatic sequencing may further stratify surveillance approaches for patients without a germline genetic driver and may also inform targeted therapeutic strategies for patients with metastatic disease.
Review • Journal
|
RET (Ret Proto-Oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1)
15h
MiR-1246 regulates the PI3K/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth. (PubMed, Mol Cell Biochem)
We confirmed that miR-1246 affects the signaling pathway of PI3K/AKT via targeting PIK3AP1 and inhibits the development of thyroid cancer. Thus, miR-1246 is a new therapeutic target for thyroid cancer.
Journal
|
IGF1 (Insulin-like growth factor 1) • MIR1246 (MicroRNA 1246)
|
miR-1246 overexpression
14h
Gastric glomus tumor diagnosed by fine needle aspiration of the stomach: A report of two cases and review of the literature. (PubMed, Diagn Cytopathol)
A definitive diagnosis was not made based on FNA. Familiarity with glomus tumors in the GI system and procurement of adequate material for cell block allowing the use of immunohistochemistry may allow an accurate preoperative diagnosis.
Clinical • Review • Journal
|
SYP (Synaptophysin)
14h
SMARCA4/BRG1-Deficient Sinonasal Carcinoma: Morphologic Spectrum of an Evolving Entity. (PubMed, Arch Pathol Lab Med)
Inclusion of SMARCA4 in the immunohistochemical panel for diagnostic workup of all sinonasal NEC and TCS phenotypes will facilitate their early recognition. Comprehensive germline and somatic mutational analyses of these tumors are necessary for further insights into their molecular pathogenesis.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2) • SYP (Synaptophysin)
1d
REGOMUNE: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (clinicaltrials.gov)
P1/2, N=482, Recruiting, Institut Bergonié | Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Dec 2020
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK positive • ALK mutation • ROS1 positive
|
Bavencio (avelumab) • Stivarga (regorafenib)
1d
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer. (PubMed, Endocr Relat Cancer)
Our study confirms that hypomethylation-mediated overexpression of TREM1 in PTC cells promotes an immunosuppressive microenvironment by enhancing Treg infiltration. We recommend the future use of therapeutic strategy targeting TREM1 for the treatment of PTC.
Journal
|
CD8 (cluster of differentiation 8)
|
BRAF V600E • BRAF V600
2d
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors (clinicaltrials.gov)
P1/2, N=180, Recruiting, Codiak BioSciences | Trial primary completion date: Nov 2021 --> Dec 2022
Clinical • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
exoSTING
3d
Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions. (PubMed, Medicina (Kaunas))
In addition, the similar IHC profiles of NIFTP and NEFVPTC also suggest the original criterion of <1% papillae within tumors, providing a reliable NIFTP diagnosis. Their close relationship may represent a spectrum of progressing neoplasia.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2) • NCAM1 (Neural cell adhesion molecule 1) • KRT19 (Keratin 19)
3d
LBX2-AS1 Activates FSTL3 by Binding to Transcription Factor RARα to Foster Proliferation, Migration, and Invasion of Thyroid Cancer. (PubMed, Front Genet)
The rescue experiments showed that LBX2-AS1 recruited the TF RARα to hasten the transcription activity of FSTL3 and thus promoted the development of thyroid cancer. The integrative results demonstrated that LBX2-AS1 activated FSTL3 by binding to TF RARα to hasten proliferation, migration and invasion of thyroid cancer.
Journal
|
RARA (Retinoic Acid Receptor Alpha)
3d
Omics- and Pharmacogenomic Evidence for the Prognostic, Regulatory, and Immune-Related Roles of PBK in a Pan-Cancer Cohort. (PubMed, Front Mol Biosci)
Thus, PBK is associated with survival outcome in a variety of cancers and may promote tumor development and progression by increasing immune cell infiltration into the tumor microenvironment. These findings indicate that PBK is a potential therapeutic target and has prognostic value in cancer treatment.
Journal • Pan tumor
|
CD8 (cluster of differentiation 8) • TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • PLK1 (Polo Like Kinase 1) • CD4 (CD4 Molecule) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • PBK (PDZ Binding Kinase) • CCNB1 (Cyclin B1) • E2F1 (E2F transcription factor 1)
3d
Clinical, Biochemical, Tumoural and Mutation Profile of VHL- and MEN2A-Associated Pheochromocytoma: A Comparative Study. (PubMed, World J Surg)
In contrast to world literature, our study suggests Indian VHL-PCC can be symptomatic in spite of noradrenergic phenotype, large in size and multifocal. Multiple nodules in VHL-PCC could increase risk of recurrence following subtotal adrenalectomy.
Clinical • Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
3d
Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk. (PubMed, Genes Genomics)
TRIM3 expression was downregulated in PTC tissues comparing with that in adjacent nontumorous thyroid tissues. Lower TRIM3 expression in PTC can contribute independently to a poorer prognosis by enhancing PTC proliferation and invasion, highlighting its potential as a novel therapeutic target and prognostic biomarker.
Journal
|
CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • TRIM3 (Tripartite Motif Containing 3) • VIM (Vimentin)
|
CCND1 expression • CDH1 expression • VIM expression
5d
miR-17 acts as a tumor suppressor by negatively regulating the miR-17-92 cluster. (PubMed, Mol Ther Nucleic Acids)
Thus, inhibition of miR-17 activated the expression of the oncogenic miRs, miR-18a and miR-19a. While many cancers express high levels of miR-17, linking it with tumorigenesis, we demonstrate that miR-17 inhibition does not inhibit thyroid tumor growth in SW579 and MDA-T32 ATC cells but increases expression of the other miR-17-92 family members and genes to induce cancer progression.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • CCND2 (Cyclin D2) • MIR17 (MicroRNA 17) • MIR18A (MicroRNA 18a)
|
MYC expression
5d
Upregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration. (PubMed, J Clin Lab Anal)
Our results show that SLC27A2 plays an important role in tumor proliferation and migration, providing a new putative target for the diagnosis and treatment of TC.
Journal
|
FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
5d
Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. (PubMed, Mol Carcinog)
Here, we applied the TASC gene list for classification and an algorithm that estimates immune cell abundance (TIMEx) to METABRIC transcriptomic data for ER + breast cancer patients coupled with multiplex imaging and analysis of paired tissue samples pre- and post- NET with the AI exemestane...Here, we show NET displays clear TME effects that promote the expansion of the less favorable TASC population which are correlated with TME remodeling and reshaping immune infiltration supportive of tumor progression. Our findings highlight the need to further understand the role of endocrine therapy on TME remodeling, tumor progression, and patient outcomes.
Clinical • Journal
|
ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • MCAM
|
ER positive
|
exemestane
5d
Journal
|
COL1A1 (Collagen, type I, alpha 1) • LAMC2 (Laminin subunit gamma 2) • TGFBI (Transforming Growth Factor Beta Induced)
6d
BRAF mutation test on fine-needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients. (PubMed, Cancer Med)
The BRAF mutation test in FNA samples has potential to reduce false negatives in PTC diagnosis, and therefore plays an important role in the diagnosis of thyroid nodules, especially those with an indeterminate or nondiagnostic cytology, which should be considered for repeat FNA.
Clinical • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
6d
Clinical • Enrollment change • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
irinotecan • Zepzelca (lurbinectedin)
6d
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers (clinicaltrials.gov)
P1, N=32, Recruiting, Memorial Sloan Kettering Cancer Center | N=22 --> 32
Enrollment change
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Zelboraf (vemurafenib) • Aliqopa (copanlisib)
7d
Clinical characteristics and treatment outcomes in acromegaly, a retrospective single-center case series from Thailand. (PubMed, Pan Afr Med J)
our study offers descriptive clinical data of case series of acromegalic patients, which had favorable outcomes comparable with previous reports. In addition, IGF-I index after surgery is a predictive parameter for outcome of treatment.
Retrospective data • Journal
|
IGF1 (Insulin-like growth factor 1)
7d
RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation. (PubMed, Cancer Cytopathol)
This study demonstrated that the overall RAS mutation-associated ROM in thyroid FNA was intermediate (29%), and isolated HRAS mutations appeared to have a higher ROM (27%) than NRAS and KRAS mutations (15% and 14%, respectively).
Journal
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • NRAS mutation • HRAS mutation
|
ThyGeNEXT®
7d
MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. (PubMed, Mol Cell)
Disruption of mRNA decapping in turn activates ATR, indicating transcription-replication conflicts. We propose that exosome recruitment by MYCN maintains productive transcription elongation during S phase and prevents transcription-replication conflicts to maintain the rapid proliferation of neuroendocrine tumor cells.
Journal
|
BRCA1 (Breast cancer 1, early onset) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
7d
The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib. (PubMed, Biomed Pharmacother)
It was even more efficient in forming of O-desmethyl lenvatinib than CYP3A4 in the absence of cytochrome b. The present study indicates that further research focused on drug-drug interactions, in particular on CYP3A4 and CYP1A1 modulators, is needed. This will pave new avenues towards TKIs-mediated personalized therapy.
Clinical • Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)
|
lenvatinib
7d
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (clinicaltrials.gov)
P2, N=120, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
Clinical • Trial completion date • Trial primary completion date
|
TG (Thyroglobulin)
|
recombinant human thyroid stimulating hormone for injection (rhTSH)
8d
Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms. (PubMed, Mod Pathol)
In summary, our study revealed the unique CN and mutation characteristics of gastric amphicrine carcinoma and differentiated these characteristics from those of MiNENs. These data provide a foundation for further studies on the development and progression of amphicrine carcinoma.
Journal
|
TP53 (Tumor protein P53) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
|
TP53 mutation
8d
Evaluation the Presence of SERPINA5 (Exon 3) and FTO rs9939609 Polymorphisms in Papillary Thyroid Cancer Patients. (PubMed, Asian Pac J Cancer Prev)
This study indicated that SERPINA5 rs6115G>A and rs6112T>C polymorphisms might be a novel susceptibility locus for PTC in Iranian patients. However, our findings do not support an association between FTO rs9939609 polymorphism and PTC risk.
Clinical • Journal
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
8d
Spindle cell variant of medullary thyroid carcinoma: a clinicopathologic study of four cases. (PubMed, Diagn Pathol)
We report 4 rare cases of spindle cell variant of MTC. Due to its rarity and special morphology, the diagnosis of spindle cell variant MTC relies on its morphology and immunohistochemical markers to avoid misdiagnosis.
Clinical • Journal
|
NKX2-1 (NK2 Homeobox 1) • NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
8d
Bisphenol-A exposure leads to neurotoxicity through upregulating the expression of histone deacetylase 2 in vivo and in vitro. (PubMed, Toxicology)
In addition, it was shown that repression of HDAC2 could markedly rescue the spine density impairment in the hippocampus and prevent the cognitive impairment caused by BPA exposure in mice. Collectively, HDAC2 plays an essential role in BPA-induced neurotoxicity, which provides a potential molecular target for medical intervention.
Preclinical • Journal • Epigenetic controller
|
LY9 (Lymphocyte Antigen 9) • HDAC2 (Histone deacetylase 2)
8d
Downregulation of Rap1GAP Expression Activates the TGF-β/Smad3 Pathway to Inhibit the Expression of Sodium/Iodine Transporter in Papillary Thyroid Carcinoma Cells. (PubMed, Biomed Res Int)
Additionally, the knockdown of Rap1GAP could alter the cell apoptosis, cycle, migration, invasion, and proliferation of BCPAP. The downregulation of Rap1GAP expression can activate the TGF-β/Smad3 pathway to inhibit NIS expression and alter the tumor cell functions of PTC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • SMAD3 (SMAD Family Member 3)
|
FOXP3 expression
8d
Age-specific clinicopathological characteristics and prognostic analysis of neuroendocrine carcinomas of the gallbladder. (PubMed, Cancer Med)
The overall survival of gallbladder NEC is not associated with age. In this study, surgical method and tumor size were found to be independent risk factors for NECs. In addition, NEC patients have a worse prognosis than ADC patients with similar clinical and pathological features.
Clinical • Journal
|
NCAM1 (Neural cell adhesion molecule 1)
8d
Unexpected Widespread Bone Metastases from a BRAF K601N Mutated Follicular Thyroid Carcinoma within a Previously Resected Multinodular Goiter. (PubMed, Endocr Pathol)
Uncommon BRAF non-V600E mutations have been identified and are generally believed to associate with follicular patterned tumors of low malignant potential, particularly non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTPs) (i.e., non-invasive encapsulated follicular variant PTC). We here report for the first time widespread bone metastases from a BRAF K601N mutated follicular tumor.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF mutation • BRAF K601
8d
A mimic of lung adenocarcinoma: a case report of histological conversion of metastatic thyroid papillary carcinoma. (PubMed, Histopathology)
Through the analysis of thyroid tumor and lung tumor at the age of 4 and 34 years in this patient, identical NCOA4-RET translation suggested histological conversion, which was induced probably due to high selective pressure by the treatment. As histological transformation of non-small cell lung cancer is well documented as a form of recurrence after EGFR-tyrosine kinase inhibitor treatment, the lineage conversion in association with effective treatments may be a diagnostic pitfall in the era of precision cancer medicine.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • NCOA4 (Nuclear Receptor Coactivator 4)
8d
Novel Classification of Acromegaly in Accordance with Immunohistochemical Subtypes: Is There Really a Clinical Relevance? (PubMed, Horm Metab Res)
With a similar follow-up period, the endocrine remission rates (GH<1 μg/l) in groups were 64 vs. 69%, respectively. In conclusion, classification according to immunohistochemical subtypes of growth hormone secreting adenomas may not be a qualified parameter to evaluate patients with patterns of aggressiveness, clinical outcomes, or treatment response.
Clinical • Journal
|
IGF1 (Insulin-like growth factor 1)
8d
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma (clinicaltrials.gov)
P2, N=25, Active, not recruiting, University Health Network, Toronto | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022
Clinical • Trial completion date • Trial primary completion date
|
CHGA (Chromogranin A)
|
Sutent (sunitinib)
9d
Protective Effects of Chaga Medicinal Mushroom, Inonotus obliquus (Agaricomycetes), Extract on β-Amyloid-Induced Neurotoxicity in PC12 Cells and Aging Rats: In Vitro and In Vivo Studies. (PubMed, Int J Med Mushrooms)
In aging rats, IOE can decrease the production of amyloid precursor protein (APP) and the levels of Aβ plaques in hippocampus after IOE treatment in the brain by an action that is associated with a lowering of the of IL-1β, TNF-α levels. Our findings indicate that IOE has potential neuroprotective actions against Aβ-induced neurotoxicity, which may occur through modulation of calcium channels or downstream molecules involved in inflammation.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • APP (Amyloid Beta Precursor Protein) • IL1B (Interleukin 1, beta)
9d
Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. (PubMed, Biochim Biophys Acta Rev Cancer)
Here, we summarize recent findings focused on the genomics, clinical manifestations, diagnosis, treatment and other aspects of high-grade GEP-NENs (G3). This review may help further our understanding of the carcinogenesis, diagnosis and treatment of GEP-NENs G3.
Review • Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler) • DAXX (Death-domain associated protein)
9d
miR-30b-5p inhibits proliferation, invasion, and migration of papillary thyroid cancer by targeting GALNT7 via the EGFR/PI3K/AKT pathway. (PubMed, Cancer Cell Int)
Overall, miR-30b-5p inhibited the progression of papillary thyroid carcinoma by targeting GALNT7 and inhibiting the EGFR/PI3K/AKT pathway.
Journal
|
MIR30B (MicroRNA 30b)
9d
LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway. (PubMed, Front Oncol)
PI3K inhibitor, LY294002, can block PI3K/AKT signaling, further inhibit glycolysis to disturb ATP production, and finally induce cell apoptosis. This finding would pave the way to remedy the FLT3-ITD mutant AML patients who failed with FLT3 targeted therapy.
Journal
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
|
Nexavar (sorafenib) • LY294002
9d
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway. (PubMed, Endocr Relat Cancer)
SREBP1-facilitated cell invasion could be abrogated by treatment with a YAP inhibitor such as verteporfin or genetic silencing of CYR61 or CTGF. In summary, SREBP1 upregulation can be used as a prognostic indicator for thyroid cancer, and SREBP1 overexpression is involved in cancer invasiveness, at least partly, through upregulation of CYR61/CTGF via the Hippo-YAP pathway.
Journal
|
CTGF (Connective tissue growth factor)
|
Visudyne (verteporfin)
9d
Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by Ga-DOTATOC PET/CT. (PubMed, EJNMMI Res)
SSTR recycling is faster in small-intestinal NETs than in liver, spleen and pancreas. This opens the possibility to protect normal tissues during PRRT by administering a single dose of cold peptide hours before peptide receptor radionuclide therapy (PRRT), and most likely additionally improve the availability and uptake of the therapeutic preparation in the tumors.
Journal
|
SSTR (Somatostatin Receptor)
9d
The correlation between the expression of ATF4 and procalcitonin combined with the detection of RET mutation and the pathological stage and clinical prognosis of medullary thyroid carcinoma. (PubMed, Can J Physiol Pharmacol)
The ATF4 and PCT expressions, as well as RET mutation, were significantly associated with a 5-year recurrence, while the ATF4 expression was significantly related to better 5-year survival. ATF4 and PCT expressions combined with RET mutation are related to the clinical prognosis of SMTC and can predict SMTC staging.
Clinical • Journal
|
RET (Ret Proto-Oncogene) • ATF4 (Activating Transcription Factor 4)
|
RET mutation • KIT expression • RET expression
9d
Identification of the active compounds and their mechanisms of medicinal and edible Shanzha based on network pharmacology and molecular docking. (PubMed, J Food Biochem)
The results suggested that the core targets alleviated dyspepsia by reducing the intestinal inflammatory response, increasing intestinal movement, controlling cell physiological activities, and reducing constipation. In summary, this study demonstrated the multiple compounds, targets, and pathways characteristics of Shanzha in the treatment of dyspepsia, which may provide guidance and foundations for further application of edible medicine.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • mTOR (Mechanistic target of rapamycin kinase) • MDM2 (E3 ubiquitin protein ligase) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • MAPK1 (Mitogen-activated protein kinase 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MMP9 (Matrix metallopeptidase 9) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • MAPK3 (Mitogen-Activated Protein Kinase 3)
9d
BAX gene (-248 G > A) polymorphism in a sample of patients diagnosed with thyroid cancer in the Federal District, Brazil. (PubMed, Int J Biol Markers)
BAX (-248 G > A) GG genotype carriers, or at least one mutated allele, was associated with papillary thyroid cancer in the Brazilian population studied, and the G allele presence is considered a protective factor against papillary thyroid cancer occurrence.
Clinical • Journal
|
BAX (BCL2-associated X protein)
9d
Prognostic value and non-neuroendocrine role of INSM1 in small cell lung cancer. (PubMed, Pathol Res Pract)
Our finding suggested INSM1 played more role than a NE marker, partly through down-regulating AMPK signal. INSM1 may serve as a novel prognostic marker and therapeutic target in SCLC.
Journal
|
INSM1 (INSM Transcriptional Repressor 1)
|
AMPK expression
|
cisplatin • metformin
9d
Medullary thyroid carcinoma: current clinical progress (PubMed, Dtsch Med Wochenschr)
Oncogenic mutations in the RET protooncogene occur in ~25 % of patients as part of the multiple endocrine neoplasia type 2 syndromes and are present as somatic mutations in 60 % of all MTC and up to 90 % of metastatic cases.The multi-tyrosine kinase inhibitors vandetanib and cabozantinib have been approved for progressive advanced disease but have low specificity for the RET tyrosine kinase. With the advent of highly selective RET inhibitors selpercatinib and pralsetinib, the treatment landscape has profoundly changed...They have demonstrated a favorable safety profile and high objective response rates also in previously treated MTC patients. The use of selective RET inhibitors in the first line setting is currently the subject of clinical trials.
Clinical • Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
|
Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib) • Gavreto (pralsetinib)
9d
Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review. (PubMed, Biomolecules)
The shRNA-mediated gene silencing efficiently suppressed the NNMT gene expression and exhibited a clear inhibitory effect on cell proliferation, promoting the expression of apoptosis-related proteins and modulating the cell cycle. NNMT could represent a new molecular biomarker and a new target of molecular-based therapy, although further studies on larger patient cohorts are needed to explore its biological role in HNT.
Review • Journal
|
NNMT (Nicotinamide N-Methyltransferase)
9d
Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics. (PubMed, Biomolecules)
Although a high overall diagnostic accuracy of small specimens was seen, small changes in routine practice (such as consequent inclusion of p40 and TTF-1 clone 8G7G3/1 in the IHC panel for non-small cell cancer with unclear morphology) may lead to improvement, while reducing the number of IHC stains would be preferable from a time and cost perspective.
Clinical • Journal • Real-world evidence
|
NKX2-1 (NK2 Homeobox 1)
9d
Integration and Visualization of Regulatory Elements and Variations of the EPAS1 Gene in Human. (PubMed, Genes (Basel))
The integrative map also includes 12 EPAS1 target genes and 27 interacting proteins. The study introduced the first integrative map of diverse genomics, transcriptomics, proteomics, regulomics, and interactomics data associated with EPAS1, to enable a better understanding of EPAS1 activity and regulation and support future research.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • EPAS1 (Endothelial PAS domain protein 1)
9d
A Novel Strategy for the Diagnosis of Pulmonary High-Grade Neuroendocrine Tumor. (PubMed, Diagnostics (Basel))
This article reviews the diagnostic methods of lung cancer diagnosis focused on immunostaining. In particular, we describe the usefulness of immunostaining by Stathmin-1, which is a cytosolic phosphoprotein and a key regulator of cell division due to its microtubule depolymerization in a phosphorylation-dependent manner, for the diagnosis of high-grade neuroendocrine tumors.
Review • Journal
|
NCAM1 (Neural cell adhesion molecule 1) • CHGA (Chromogranin A) • SYP (Synaptophysin)
9d
Prognostic Value of Serum Thyroglobulin and Anti-Thyroglobulin Antibody in Thyroid Carcinoma Patients following Thyroidectomy. (PubMed, Diagnostics (Basel))
These findings provide baseline information for follow-up and lifelong monitoring of thyroidectomized WDTC patients. Further research is warranted to explore more about serum TG and TGAb in thyroid carcinoma patients on a larger scale.
Clinical • Journal
|
TG (Thyroglobulin)
9d
The Diagnostic, Prognostic and Therapeutic Role of miRNAs in Adrenocortical Carcinoma: A Systematic Review. (PubMed, Biomedicines)
Unfortunately, data on the therapeutic role of miRNA are still scarce and limited mainly at the experimental level. Thus, the role of miRNA regulation in ACC remains an area of active research.
Review • Journal
|
MIR195 (MicroRNA 195) • MIR483 (MicroRNA 483)
9d
Optimizing the Schedule of PARP Inhibitors in Combination with Lu-DOTATATE: A Dosimetry Rationale. (PubMed, Biomedicines)
According to the modelling, the PARP inhibitor should be introduced approximately 24 h after the start of Lu-DOTATATE treatment and be continued for up to four weeks to optimize the TNED. Based on these results, a phase I trial assessing the combination of olaparib and Lu-DOTATATE in somatostatin receptor-positive tumours was launched in 2020 (NCT04375267).
Journal • Combination therapy
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
9d
Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma. (PubMed, Cancers (Basel))
We show that CCR7 is expressed on mRNA and protein level across normal adrenals, benign adrenocortical tumors, as well as ACCs. Given that CCR7 did not influence survival in ACC, it is probably not involved in tumor progression, but it could play a role in adrenocortical homeostasis.
Clinical • Clinical data • Journal
|
CCR7 (Chemokine (C-C motif) receptor 7)
|
CCR7 expresion
9d
Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target? (PubMed, Cancers (Basel))
Radiolabelled PSMA-ligands may, in the future, represent a theranostic approach with only minor side effects for a few individual selected patients with ATC and PDTC who need alternative treatment options in case of progression when established therapies are no longer effective. However, due to the small sample size of our collective, larger studies are needed to allow for a final evaluation on the significance of PSMA-targeted diagnostic and therapy for ATC and PDTC.
Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 positive
9d
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals. (PubMed, Cancers (Basel))
The intense efforts in optimizing CCK2R targeting radiopharmaceuticals has led to new substances for clinical use, as shown in first imaging studies in patients with advanced medullary thyroid cancer. The first clinical results suggest that the wider clinical implication of CCK2R-targeted radiopharmaceuticals is reasonable.
Preclinical • Review • Journal
|
GAST (Gastrin 2)
9d
Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer. (PubMed, Cancers (Basel))
In multivariable analysis, postoperative serum calcitonin, postoperative serum CEA, and LNR were identified as a predictor of disease-free survival (p < 0.05). LNR can potentially predict structural recurrence as a quantitative evaluation tool for lymph node metastasis in patients with MTC.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
9d
Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAF-Mutant Advanced Papillary Thyroid Carcinoma. (PubMed, Cancers (Basel))
Coexistence of mutations in BRAF and genes encoding FGs was associated with high mortality. Identification of FG mutation in BRAF-mutant PTCs may be valuable in risk stratifying this subtype.
Clinical • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
9d
MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells. (PubMed, Cancers (Basel))
The negative impact on NIS expression induced by the MAPK-activating alterations, NRAS Q61R and BRAF V600E, was partially reversed by the presence of the MEK 1/2 inhibitors AZD6244 and CH5126766. Conversely, the presence of active RAC1 considerably improved the rescue of NIS expression in BRAF V600E thyroid cells treated with MEK inhibitors. Overall, our data support an important role for RAC1 signaling in enhancing MAPK inhibition in the context of RAI therapy in DTC, opening new opportunities for therapeutic intervention.
Journal
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
|
BRAF V600E • NRAS mutation • BRAF V600 • NRAS Q61R • NRAS Q61
|
Koselugo (selumetinib) • VS-6766
9d
Development of Functional Thyroid C Cell-like Cells from Human Pluripotent Cells in 2D and in 3D Scaffolds. (PubMed, Cells)
As well as expressing C cell lineage relative to follicular-lineage markers by qPCR (quantitative polymerase chain reaction) and immunolabelling, these cells by ELISA (enzyme-linked immunoassay) exhibited functional properties in vitro of calcitonin storage and release of calcitonin on calcium challenge. This method will contribute to developmental studies of the human thyroid gland and facilitate in vitro modelling of medullary thyroid carcinoma and provide a valuable platform for drug screening.
Journal
|
IGF1 (Insulin-like growth factor 1)
9d
Pathogenic Mitochondrial DNA Mutation Load Inversely Correlates with Malignant Features in Familial Oncocytic Parathyroid Tumors Associated with Hyperparathyroidism-Jaw Tumor Syndrome. (PubMed, Cells)
MtDNA sequencing revealed a rare ribosomal RNA mutation in the germline of all HPT-JT affected individuals whose pathogenicity was functionally evaluated via cybridization technique, and which was counter-selected in the most aggressive infiltrating carcinoma, but positively selected in adenomas. In all tumors different somatic mutations accumulated on this genetic background, with an inverse clear-cut correlation between the load of pathogenic mtDNA mutations and the indolent behavior of neoplasms, highlighting the importance of the former both as modifiers of cancer fate and as prognostic markers.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
9d
Death-Associated Protein Kinase 1 Inhibits Progression of Thyroid Cancer by Regulating Stem Cell Markers. (PubMed, Cells)
Mechanistic studies suggest that DAPK1 may modulate the expression of stem cell markers through the inhibition of β-catenin pathways. These findings were consistent with the public data and our thyroid tissue analysis, which showed higher DAPK1 expression was associated with advanced-stage papillary thyroid cancer with a higher stemness index and lower disease-free survival.
Journal
|
KLF4 (Kruppel-like factor 4) • POU5F1 (POU Class 5 Homeobox 1) • SOX2 • DAPK1 (Death Associated Protein Kinase 1) • NANOG (Nanog Homeobox)
9d
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. (PubMed, Cells)
A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients...PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.
Journal • Review • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay • PD-L1 IHC 28-8 pharmDx
|
Keytruda (pembrolizumab)
13d
Five genes involved in circular RNA-associated competitive endogenous RNA network correlates with metastasis in papillary thyroid carcinoma. (PubMed, Math Biosci Eng)
Overall, we identified several potential targets and regulatory mechanisms involved in PTC. APOA2, CCL20, LPAR5, MFGE8, and TIMP1 may be correlated with PTC metastasis.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1) • CCL20 (C-C Motif Chemokine Ligand 20) • MIR199B (MicroRNA 199b) • MIR7 (MicroRNA 7)
13d
EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine. (PubMed, Sci Rep)
The EZH2 inhibitor GSK126 also repressed proliferation of CNDT2.5 cells. Exposure of GOT1 three-dimensional cell spheroids to CPI-1205 or metformin arrested cell proliferation and decreased spheroid size. These novel findings support a possible role of EZH2 as a candidate oncogene in SI-NETs, and suggest that CPI-1205 and metformin should be further evaluated as therapeutic options for patients with SI-NETs.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
GSK2816126 • metformin • lirametostat (CPI-1205)
13d
Monoallelic deleterious MUTYH germline variants as a driver for tumorigenesis. (PubMed, J Pathol)
© 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd
Journal
|
MUTYH (MutY homolog)
13d
Utility of SOX11 for the Diagnosis of Solid Pseudopapillary Neoplasm of the Pancreas on Cytological Preparations. (PubMed, Cytopathology)
SOX11 detected by ICC can serve as a useful diagnostic marker for SPN, in addition to beta catenin, and can be performed on cytological smears in cases without a CB preparation.
Journal
|
HMGB1 (High Mobility Group Box 1) • SOX11 (SRY-Box Transcription Factor 11)
14d
LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. (PubMed, Cell Death Dis)
Our findings suggest MIAT may inhibit EZH2 expression and promote PTC cell invasion via the miR-150/EZH2 pathway. Therefore, MIAT may serve as a valuable prognostic biomarker and therapeutic target for PTC.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • MIR150 (MicroRNA 150)
14d
Thyroid lobectomy for low-risk thyroid cancers. (PubMed, Ann R Coll Surg Engl)
Lobectomy-only appears to be the current surgical practice in two-thirds of patients presenting to our regional units with differentiated thyroid carcinoma. In the context of the current drive to reduce the extent of treatment for low-risk thyroid cancer, there is a need for a more homogeneous approach to these patients and for protocols for long-term follow-up after lobectomy-only.
Journal
|
THY1 (Thy-1 membrane glycoprotein)
14d
General Characteristics and Association of Myeloid Neoplasm with Thyroid Cancer (ASH 2021)
Thyroid cancer proceeded AML or MDS by 2.5 years, while thyroid cancer happened around the same year (0.09) with MPNs (p= 0.04) Table 1 A hypomethylating agent (HMA) based therapy for myeloid neoplasm was the most commonly used in 15 (42.86%), other therapies included cytarabine (5), cladribine (4) & fludarabine (3) based .37 pts (67.27 %) achieved complete remission, while 18 (32.73%) underwent stem cell transplantation. DTC did occur with MPNs as well with CML most frequent subtype. Prospective studies need to be done to further elucidate the relationship between DTC & MPN.
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ASXL1 (ASXL Transcriptional Regulator 1)
|
TP53 mutation • FLT3 mutation • ASXL1 mutation
|
cytarabine • cladribine • fludarabine IV
14d
Chronic Myeloid Leukemia Following Exposure to Radioactive Iodine (I 131 ): A Systematic Review (ASH 2021)
Conclusion Although the risk of t-CML appears to be low based on current reports, it should not be disregarded. Further studies are needed to establish or refute a causal relationship.
Review
|
RET (Ret Proto-Oncogene)
|
RET mutation
14d
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm (clinicaltrials.gov)
P2, N=23, Recruiting, Peking Union Medical College Hospital | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
Tyvyt (sintilimab) • Epidaza (chidamide)
14d
Case report: composite pancreatic intraductal papillary mucinous neoplasm and neuroendocrine tumor: a new mixed neuroendocrine-non-neuroendocrine neoplasm? (PubMed, Diagn Pathol)
Our case provides evidence of a common origin for mixed IPMN-NET with composite growth features. Our result and literature review indicate that KRAS mutation might be a driver event underlying the occurrence of MiNEN. We also recommend the inclusion of mixed non-invasive exocrine neoplasms and neuroendocrine neoplasms into MiNEN.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • KMT2C (Lysine Methyltransferase 2C)
|
KRAS mutation • MLL mutation
14d
Long noncoding RNA SNHG6 promotes papillary thyroid cancer cells proliferation via regulating miR-186/CDK6 axis. (PubMed, Gland Surg)
SNHG6 can promote the expression of CDK6 by regulating miR-186. SNHG6 is highly expressed in PTC and can promote the proliferation of PTC cells by regulating the miR-186/CDK6 axis, which is expected to become a potential therapeutic target for PTC.
Journal
|
CDK6 (Cyclin-dependent kinase 6)
|
CDK6 expression
14d
MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer. (PubMed, Front Oncol)
With the adoption of inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6i) in combination with endocrine therapy as standard of care for the treatment of advanced and metastatic estrogen receptor positive (ER+) breast cancer, the search is now on for novel therapeutic options to manage the disease after the inevitable development of resistance to CDK4/6i. In this review we will consider the integral role that the p53/MDM2 axis plays in the interactions between CDK4/6, ERα, and inhibitors of these molecules, the current preclinical evidence for the efficacy of MDM2 inhibitors in ER+ breast cancer, and discuss the possibility of targeting the p53/MDM2 via inhibition of MDM2 in the CDK4/6i resistance setting.
Review • Journal
|
ER (Estrogen receptor)
|
HR positive • ER positive
14d
Surgical treatment and management of syndromic paraganglioma. The experience of a referral center. (PubMed, Ann Ital Chir)
Syndromic PGLs are rare conditions; surgery is the treatment of choice. Adrenal PGL requires laparoscopic adrenalectomy with transperitoneal lateral approach as gold standard. For genetic syndrome such as MEN2 and VHL, laparoscopic cortical sparing adrenalectomy of at least one gland should be considered.
Journal
|
RET (Ret Proto-Oncogene) • NF1 (Neurofibromin 1) • VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHD (Succinate Dehydrogenase Complex Subunit D)
|
RET mutation • VHL mutation • SDHB mutation
14d
Papillary Thyroid Carcinoma Landscape and Its Immunological Link With Hashimoto Thyroiditis at Single-Cell Resolution. (PubMed, Front Cell Dev Biol)
Our results provided a single-cell landscape of human PTC. These data would deepen the understanding of PTC, as well as the immunological link between PTC and HT.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
14d
C-kit, flt-3, PDGFR-β, and VEGFR2 expression in canine adrenal tumors and correlation with outcome following adrenalectomy. (PubMed, Can J Vet Res)
Receptor tyrosine kinases are not overexpressed in canine adrenal tumors compared to normal adrenal tissue. Therapeutic inhibition of these receptors may still represent an effective approach in cases where receptor activation is present.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • KDR (Kinase insert domain receptor)
|
KIT expression • KDR expression
15d
Fine-needle Aspiration Washout Precipitation Specimens: An Acceptable Supplement to Genetic Mutation Detection of Thyroid Nodules. (PubMed, Technol Cancer Res Treat)
Furthermore, the BRAF V600E mutation status using FNA washout precipitation specimens provided a 100.0% positive predictive value for diagnosing papillary thyroid carcinoma in patients with The Bethesda system for reporting thyroid cytopathology (TBSRTC) V. Besides, the BRAF V600E mutation status was positive in 90.9% (10/11) FNA washout precipitation specimens from patients with capsule invasion, achieving a higher overall sensitivity of 100.0%, compared with 57.1% of FNA washout precipitation specimens from patients without capsule invasion. These results suggested that FNA washout precipitation specimens might be a valuable supplementary sample type for detecting the BRAF V600E mutation in patients with thyroid nodules, especially with thyroid capsule invasion.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E
15d
Intrasalivary Thymic Carcinoma: A Case Report and Literature Review. (PubMed, Head Neck Pathol)
We postulate that similar cases should be designated as intrasalivary thymic carcinoma analogically to similar thyroid tumors. Our case and the limited literature data indicate they should be distinguished from conventional squamous cell carcinoma of major salivary glands due to their rather favorable prognosis.
Clinical • Review • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • TP63 (Tumor protein 63)
|
CD5 positive
15d
The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. (PubMed, J Thorac Oncol)
In 2021, there is greater emphasis throughout the book on advances in molecular pathology across all tumor types. Major features within this edition are 1) broader emphasis on genetic testing than in the 2015 WHO Classification, 2) a chapter entirely dedicated to the classification of small diagnostic samples, 3) continued recommendation to document percentages of histological patterns in invasive non-mucinous adenocarcinomas, with utilization of these features to apply a formal grading system, as well as using only invasive size for T-factor size determination in part lepidic non-mucinous lung adenocarcinomas as recommended by the 8 Edition TNM Classification, 4) recognition of spread through airspaces (STAS) as a histological feature with prognostic significance, 5) moving lymphoepithelial carcinoma to squamous cell carcinomas, 6) update on evolving concepts in lung neuroendocrine neoplasm classification, 7) recognition of bronchiolar adenoma/ciliated muconodular papillary tumor (BA/CMPT) as a new entity within the adenoma subgroup, 8) recognition of thoracic SMARCA4-deficient undifferentiated tumor, and 9) inclusion of essential and desirable diagnostic criteria for each tumor.
Review • Journal
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
15d
Clinical • Observational data • Journal
|
TG (Thyroglobulin)
16d
SSTR2 is a prognostic factor and a promising therapeutic target in glioma. (PubMed, Am J Transl Res)
Kaplan-Meier analysis indicated that SSTR2 high expression was a good prognostic factor in glioma. In summary, this study demonstrated that SSTR2 might be a valuable prognostic factor and therapeutic target in certain glioma subtypes.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR2 expression
17d
Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Anti-Tumor Activity. (PubMed, Mol Cancer Ther)
Strikingly, mTOR inhibitor treatment significantly reduced lung metastatic lesions, with the decreased expression of Snail in xenograft tumors. Our data demonstrates that mTOR pathway blockade represents a novel treatment strategy for HCC.
Journal
|
CCNA2 (Cyclin A2)
17d
Single-Cell Transcriptomic Analysis of Ecosystems in Papillary Thyroid Carcinoma Progression. (PubMed, Front Endocrinol (Lausanne))
Three CAF subtypes in Ca and LN were identified, which may be due to mutual transitions. Our data provide new insights into the PTC ecosystem and highlight the differences in ecosystems in PTC progression, which updates our understanding of PTC biology and will improve individualized patient treatment.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
CD4 expression
17d
Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy. (PubMed, Front Mol Biosci)
In two cohort studies of patients receiving immunotherapy, high-ICI-score group showed notable therapeutic effects and clinical advantages compared to those with lower ICI scores. These results demonstrate that ICI score acts as an effective prognostic indicator and predictor of response to immunotherapy.
Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden)
17d
Relationships Between Circulating Tenascin-C Levels and Gonadal Hormones in Male Patients with Depressive Disorder: A Retrospective, Cross-Sectional Study. (PubMed, Lab Med)
Increased TNC levels may predict imbalance between T and E2 in patients with depression, and gonadal hormones may modulate TNC expression in vivo.
Observational data • Retrospective data • Journal
|
CRP (C-reactive protein)
17d
Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors. (PubMed, J Pathol Clin Res)
Similar to oncocytic thyroid tumors, PTC-TCV is characterized by mtDNA mutations, massive accumulation of mitochondria, and loss of OXPHOS integrity. IHC loss of NDUFS-4 can be used as a surrogate marker for OXPHOS disruption and to reliably diagnose PTC-TCV.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
17d
Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course. (PubMed, PLoS One)
The incidence of severe haematotoxicity was low with extensive screening and monitoring. The vast majority of patients (96/100) was not restricted in treatment continuation by haematotoxicity; therefore, our selection criteria appeared appropriate for safe PRRT treatment. Baseline parameters showed limited correlation with the degree of decline in haematological values.
Clinical • Journal
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lutathera (lutetium Lu 177 dotatate)
17d
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol)
Lu-Dotatate treatment did not significantly improve median overall survival versus high-dose long-acting octreotide. Despite final overall survival not reaching statistical significance, the 11·7 month difference in median overall survival with Lu-Dotatate treatment versus high-dose long-acting octreotide alone might be considered clinically relevant. No new safety signals were reported during long-term follow-up.
Clinical • P3 data • Journal
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Sandostatin LAR Depot (octreotide acetate)
17d
Poorly differentiated thyroid carcinoma arising from a lithium-induced goiter in a patient with schizophrenia: a case report. (PubMed, Thyroid Res)
Thyroid examination of psychiatric patients who develop goiter due to long-term lithium treatment should be monitored regularly, and appropriate investigations and surgery should be performed in a timely manner if the goiter is growing rapidly.
Clinical • Journal
|
BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase) • TG (Thyroglobulin)
|
BRAF mutation
17d
A Case of Neuroendocrine Carcinoma Originating from the Papilla of Vater (PubMed, Gan To Kagaku Ryoho)
Although the patient declined adjuvant chemotherapy, she had to start chemotherapy with carboplatin and etoposide because multiple liver metastases, lymph node metastasis, and peritoneal dissemination occurred 6 months after surgery. The prognosis of the disease is poor when surgery alone is performed. Adjuvant chemotherapy, in addition to surgery, may be necessary.
Clinical • Journal
|
NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
|
carboplatin • etoposide IV
17d
Mixed neuroendocrine non-neuroendocrine neoplasm: a case report and review. (PubMed, Clin J Gastroenterol)
MiNEN is a malignant tumor that requires early detection and treatment but is a rare disease for which no method has been established. We found that EUS-FNA and immunostaining are effective diagnostic methods for MiNEN.
Clinical • Review • Journal
|
CHGA (Chromogranin A) • SYP (Synaptophysin)
17d
Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics. (PubMed, Cells)
The randomly selected DPP calnexin was further confirmed with immunoprecipitation (IP) and Western blot (WB). These findings provide the first DPP profiling, phosphorylation-mediated molecular network alterations, and the key kinase profiling in NF-PitNET pathogenesis, which are a precious resource for understanding the biological roles of protein phosphorylation in NF-PitNET pathogenesis and discovering effective phosphoprotein biomarkers and therapeutic targets and drugs for the management of NF-PitNETs.
Journal
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • NEK1 (NIMA Related Kinase 1)
17d
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. (PubMed, Nat Commun)
Moreover, potential vascular-immune crosstalk in PTC provides theoretical basis for combined anti-angiogenic and immunotherapy. Together, our findings provide insight into the PTC ecosystem that suggests potential prognostic and therapeutic implications.
Journal
|
BRAF (B-raf proto-oncogene)
17d
Hereditary paraganglioma presenting with atypical symptoms: Case report. (PubMed, Medicine (Baltimore))
Preceding symptoms of the presented case might be caused by PGL. Although PPGL is a rare disease, especially in children, it should be considered in differential diagnosis when various unexplained symptoms persist.
Clinical • Journal
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
17d
Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks. (PubMed, Arch Biochem Biophys)
Drug repositioning and molecular docking simulations revealed that 5 drugs (prochlorperazine, meclizine, rottlerin, cephaeline, and tretinoin) may be useful in the treatment of PTC. Consequently, we report here biomolecule candidates that may be considered as prognostic biomarkers or potential therapeutic targets for further experimental and clinical trials for PTC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • CDK2 (Cyclin-dependent kinase 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • HDAC1 (Histone Deacetylase 1) • HDAC2 (Histone deacetylase 2) • MIR193B (MicroRNA 193b) • MIR30B (MicroRNA 30b) • CDK1 (Cyclin-dependent kinase 1) • MIR424 (MicroRNA 424) • MIR15B (MicroRNA 15b)
|
prochlorperazine maleate
19d
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov)
P2, N=40, Recruiting, Antonio Fojo | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023
Trial completion date • Trial primary completion date
|
SSTR (Somatostatin Receptor) • CHGA (Chromogranin A)
|
SSTR positive
|
Somatuline Depot (lanreotide prolonged-release subcutaneous)
19d
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • HRD (Homologous Recombination Deficiency)
|
HER-2 negative
|
Zepzelca (lurbinectedin)
20d
Long non-coding RNA LIFR-AS1 suppressed the proliferation, angiogenesis, migration and invasion of papillary thyroid cancer cells via the miR-31-5p/SIDT2 axis. (PubMed, Cell Cycle)
LIFR-AS1 sponged miR-31-5p to upregulate SIDT2, thereby inhibiting the viability, proliferation, migration, invasion, and the secretion of vascular endothelial growth factor (VEGF) of PTC cells and angiogenesis of human umbilical vein endothelial cells (HUVECs). This paper demonstrates that LIFR-AS1/miR-31-5p/SIDT2 axis modulated the development of PTC.
Journal
|
LIFR (LIF Receptor Subunit Alpha) • MIR31 (MicroRNA 31)
20d
Clinical • New trial
|
Cancer antigen 19-9
20d
Reproducible Histopathologic Features in Cases of Basal Cell Carcinoma With Neuroendocrine Expression: A Clinicopathologic Study of 24 Cases With a Potential Diagnostic Pitfall. (PubMed, Am J Dermatopathol)
Neuroendocrine expression in BCCs is yet uncertain, and further studies are required to fully understand this phenomenon. To avoid diagnostic pitfalls, dermatopathologists must be aware of these unusual histopathologic features and aberrant immunostaining in such tumors; hence, it is advised to perform a thorough histologic inspection.
Clinical • Journal
|
NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
20d
[VIRTUAL] RET Gene Fusion Incidence in a 95-Sample Cohort of Papillary Thyroid Cancers in Canada (AMP 2021)
In this profiling of Canadian PTC cases for RET fusions, 3.2% harbored a RET fusion, in line with largescale profiling of American PTC specimens, where RET fusions were found in 13/560 (2.32%; Project Genie) and 33/484 (6.8%; TCGA) cases. The 2 observed RET fusions, NCOA4-RET and CCDC6-RET, are consistent with the most common fusions reported in the literature. In this study cohort, the combined frequency of all other detected fusion driver genes was higher than that of RET, underscoring the importance of screening PTC specimens using an NGS multi-target partner-agnostic molecular assay.
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR3 (Fibroblast growth factor receptor 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR1 (Fibroblast growth factor receptor 1) • NRG1 (Neuregulin 1) • STRN (Striatin) • CCDC6 (Coiled-Coil Domain Containing 6) • NCOA4 (Nuclear Receptor Coactivator 4) • CUX1 (cut like homeobox 1) • CSF1 (Colony stimulating factor 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PDGFB (Platelet Derived Growth Factor Subunit B) • TNS3 (Tensin 3)
|
BRAF V600E • BRAF V600 • RET fusion • FGFR2 fusion • ALK fusion • RET rearrangement • ROS1 fusion • BRAF fusion • FGFR3 fusion • NCOA4-RET fusion • STRN-ALK fusion • MET fusion • CUX1-BRAF fusion
20d
[VIRTUAL] Comprehensive Genomic Profiling Via Plasma Based Circulating Tumor DNA Assay Does Not Result in Significant OffLabel Use of Precision Oncology Therapeutics (AMP 2021)
Patients with comprehensive genomic profiling results most likely to lead to off-label therapy had virtually no off-label therapy prescribed (0.8%). CGP via a well-validated NGS panel with clear reporting does not appear to lead to inappropriate utilization, and patients who would be missed by an indication-specific targeted test were directed to on-label therapy.
BRCA Biomarker • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Guardant360® CDx
20d
[VIRTUAL] Diagnostic and Clinical Utility of OncoScan CNV Plus Assay Testing in Pediatric Solid Tumors (AMP 2021)
The validation studies and clinical cases analyzed have established OS+ as a reliable test for detection of CNAs, cnLOH, and SMs in FFPE neoplasms. The availability, cost, turn-around time, and comprehensiveness are factors that make OS+ a principal test for pediatric solid tumor analysis at our institution.
Clinical
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
BRAF V600E • BRAF V600 • NRAS G13 • KRAS deletion
|
OncoScan™ CNV Plus Assay
20d
[VIRTUAL] Molecular Profiling in Thyroid Cancer Using Next-Generation Sequencing to Differentiate Rare Cases of Papillary Thyroid Hyperplasia from Papillary Thyroid Carcinoma (AMP 2021)
This study demonstrates the utility of molecular testing as an adjunct to histopathological evaluation in definitive diagnosis and differentiation of PTH from papillary carcinoma. Next-generation sequencing with targeted DNA and RNA panels will be beneficial for both known and novel variant or fusion detection in suspect cases.
Clinical • Next-generation sequencing
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ERG (ETS Transcription Factor ERG) • ETV1 (ETS Variant Transcription Factor 1) • KRT19 (Keratin 19)
|
BRAF V600E • NRAS mutation • BRAF V600 • NRAS Q61R • NRAS Q61
20d
[VIRTUAL] CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation Sequencing (NGS) (AMP 2021)
The CANTRK study demonstrated a high level of agreement in detection of NTRK fusions by NGS RNA testing across different NGS panels. Fusions not detected by certain panels were due either to absence of targets in amplicon primer panels, or potential bioinformatic challenges. Issues encountered during the study, such as defining quality criteria for reporting a positive result, types of results requiring confirmation, and reporting requirements, will be used to formulate a best practice guideline for analysis and reporting of gene fusions detected by NGS methods.
Next-generation sequencing
|
ALK (Anaplastic lymphoma kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • TPM3 (Tropomyosin 3) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ETV6-NTRK3 fusion • ALK fusion • ROS1 fusion • TPM3-NTRK1 fusion • LMNA-NTRK1 fusion • ALK-ROS1 fusion • NTRK fusion
|
Archer® FusionPlex® Lung Kit • Oncomine Focus Assay • Oncomine Precision Assay • Oncomine™ Comprehensive Assay v3M
21d
Antidepressant-like effect of Ganoderma lucidum spore polysaccharide-peptide mediated by upregulation of prefrontal cortex brain-derived neurotrophic factor. (PubMed, Appl Microbiol Biotechnol)
PGL decreased serum corticosterone levels and increased BDNF mRNA and protein levels and increased synapsin I and PSD95 levels in the prefrontal cortex. This effect was completely blocked by pretreatment with the BDNF antagonist K252a, indicating that PGL increased synaptic proteins in a BDNF-dependent manner.Key points• An antidepressive polysaccharide-peptide PGL was isolated from G. lucidum spores.• PGL protected PC12 nerve cells from the toxicity of corticosterone.• PGL upregulated BDNF expression and influenced key factors in the prefrontal cortex.
Journal
|
BDNF (Brain Derived Neurotrophic Factor)
21d
Case Report: Medullary Thyroid Cancer Workup Initiated by Unexpectedly High Procalcitonin Level-Endocrine Training Saves Life in the COVID-19 Unit. (PubMed, Front Endocrinol (Lausanne))
The attending infectologist happened to be a colleague who spent some time, as part of her internal medicine rotation, in the Endocrine Ward and recalled that medullary thyroid cancer might be the cause. This led to the timely workup and treatment of the medullary cancer.
Clinical • Retrospective data • Review • Clinical Trial,Phase II • Journal
|
CRP (C-reactive protein)
21d
Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report. (PubMed, J Med Case Rep)
Although rare, it is important to recognize that pneumatosis intestinalis can occur in association with lenvatinib and should be differentiated from intestinal perforation. Pneumatosis intestinalis association with lenvatinib can be improved by withdrawal.
Clinical • Journal
|
TG (Thyroglobulin)
|
Avastin (bevacizumab) • Sutent (sunitinib) • lenvatinib
21d
Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features. (PubMed, Pathol Oncol Res)
Syntaxin-1 and INSM1 are sensitive and specific markers of breast tumors with neuroendocrine features, outperforming chromogranin A and CD56. We recommend syntaxin-1 and INSM1 to be included in the routine neuroendocrine immunohistochemical panel.
Journal
|
NCAM1 (Neural cell adhesion molecule 1) • CHGA (Chromogranin A) • SYP (Synaptophysin)
21d
Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). (PubMed, Exp Ther Med)
Despite these recent findings yielding promising observations, further research is necessary. The present review therefore summarizes the existing knowledge and recent advancements in the exploration of biochemical markers for NENs, with focus on gastroenteropancreatic-neuroendocrine tumors.
Journal • Review
|
GAST (Gastrin 2)
|
NETest®
21d
Focal neuroendocrine carcinoma mixed with adenocarcinoma of the gallbladder with aggressive lymph node metastasis in a patient who did not meet the mixed neuroendocrine-non-neuroendocrine neoplasm criteria. (PubMed, Clin J Gastroenterol)
The final diagnosis was adenocarcinoma of the gallbladder with focal NEC (< 30%), which did not meet the criteria for mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN). Postoperatively, she completed 4 cycles of adjuvant chemotherapy for NEC (Cisplatin plus Etoposide), and no recurrence was observed after 12 months.
Clinical • Journal
|
SYP (Synaptophysin)
|
cisplatin • etoposide IV
21d
Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway. (PubMed, PLoS One)
The study briefly revealed the key prognostic biomarker genes in the apoptotic pathway whose altered expression is associated with PTC progression and aggressiveness. In addition to this, risk assessment models proposed here can help in efficient management of PTC patients.
Clinical • Journal
|
ANXA1 (Annexin A1) • GPX4 (Glutathione Peroxidase 4) • BNIP3L (BCL2 Interacting Protein 3 Like)
21d
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. (PubMed, Int J Mol Sci)
For example, 58.9% of SCC patients, 33.5% of AC/UrCs patients, and 79.3% of Sq-BLCA patients would be eligible for at least one of the analyzed targets. In conclusion, our findings hold promise for targeted therapeutic approaches in selected patients in the future, as various drugs could be applied according to the biomarker status.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MSI (Microsatellite instability) • FGFR3 (Fibroblast growth factor receptor 3) • TROP2 (Trophoblast Cell Surface Antigen 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
21d
A Novel Isogenic Human Cell-Based System for MEN1 Syndrome Generated by CRISPR/Cas9 Genome Editing. (PubMed, Int J Mol Sci)
The high potential of these cell lines to differentiate into the endodermal lineage in defined conditions ensures the next steps in the development of more specialized cells that are commonly affected in MEN1 patients, such as parathyroid or pancreatic islet cells. We anticipate that this isogenic system will be broadly useful to comprehensively study MEN1 gene function across different contexts, including in vitro modeling of MEN1 syndrome.
Journal
|
MEN1 (Menin 1)
21d
Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. (PubMed, Molecules)
Using immunohistochemistry, we localized PSMA expression to tumor vasculature. Our study provides the first direct evidence of PSMA overexpression in PPGLs which could translate to therapeutic and diagnostic applications of anti-PSMA radio-conjugates in high-risk PPGLs.
Journal
|
EPAS1 (Endothelial PAS domain protein 1) • FOLH1 (Folate hydrolase 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
|
FOLH1 expression
21d
Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators. (PubMed, Cancers (Basel))
This is the first report to demonstrate the molecular differentiation of STC and DPC. Overall, the integral molecular profile performed excellent discrimination and denoted an exponential function to predict the probability of DPC.
Journal • Mismatch repair
|
CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
|
MSI-H/dMMR • CDK6 expression
21d
Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer. (PubMed, Cancers (Basel))
RAC1 signals through PAK1 and PIP5K to promote ARP2/3-mediated actin polymerization, and the recruitment and binding of the actin anchoring protein EZRIN to NIS, promoting its residency and function at the PM of normal and TC cells. Besides providing novel insights into the regulation of NIS localization and function at the PM of TC cells, our results open new venues for therapeutic intervention in TC, namely the possibility of modulating abnormal SRC signaling in refractory TC from a proliferative/invasive effect to the re-sensitization of these tumors to RAI therapy by inducing NIS retention at the PM.
Journal
|
RAC1 (Rac Family Small GTPase 1)
21d
Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia. (PubMed, Cancers (Basel))
This patient-centered approach permits postponing thyroid surgery in children until their adolescence/adulthood. At the same time, we confirmed that genetic screening allows finding hidden MTC cases that otherwise would be diagnosed much later.
Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
21d
Papillary Thyroid Cancer Prognosis: An Evolving Field. (PubMed, Cancers (Basel))
Additionally, the prognostic stratification systems have been profoundly modified over the last decade, with a view to refine patients' staging and being able to choose a clinical approach tailored on single patient's needs. Here, we will briefly discuss the recent changes in the clinical management of thyroid nodules, and review the current staging systems of thyroid cancer patients by analyzing promising clinicopathological features (i.e., gender, thyroid auto-immunity, multifocality, PTC histological variants, and vascular invasion) as well as new molecular markers (i.e., BRAF/TERT promoter mutations, miRNAs, and components of the plasminogen activating system) potentially capable of ameliorating the prognosis of PTC patients.
Review • Journal
|
BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
|
BRAF mutation • TERT promoter mutation • TERT mutation
21d
DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with I. (PubMed, Eur J Nucl Med Mol Imaging)
This study provides novel data about the ex vivo DSB repair in internally irradiated PBMCs of patients before radionuclide therapy. Our findings show, in a large patient sample, that efficient repair occurs after internal irradiation with 50 mGy absorbed dose, and that the induction and repair rate after I exposure is comparable to that of external irradiation with γ- or X-rays.
Preclinical • Journal
|
TP53BP1 (Tumor Protein P53 Binding Protein 1)
21d
NRXN2 Possesses a Tumor Suppressor Potential via Inhibiting the Growth of Thyroid Cancer Cells. (PubMed, Comput Math Methods Med)
Functionally, we proved that overexpressing NRXN2 resulted in an inhibition of THCA cell proliferation, migration, and invasion in vitro. Collectively, our study demonstrated that, for the first time, NRXN2 behaved as an inhibitor of neoplasm and a promising biomarker in THCA.
Journal
|
NCAM1 (Neural cell adhesion molecule 1)
21d
RET Proto-Oncogene Mutational Analysis in 45 Iranian Patients Affected with Medullary Thyroid Carcinoma: Report of a New Variant. (PubMed, J Thyroid Res)
RET mutation detection is a promising/golden screening test and provides an accurate presymptomatic diagnostic test for at-risk carriers (the siblings and offspring of the patients) to consider prophylactic thyroidectomy. Thus, according to the ATA recommendations, the screening of the RET proto-oncogene is indicated for patients with MTC.
Clinical • Journal
|
RET (Ret Proto-Oncogene)
|
RET M918T • RET mutation • RET C634R • RET C634Y • RET C618R • RET C634* • RET C634F • RET positive
21d
Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort. (PubMed, Sci Rep)
Treatment options included surgery, somatostatin analogs (SSA), and chemotherapy with either platinum-based or temozolomide-based regimens...Prognosis is typically poor, though select cases may respond to treatment with SSA and/or chemotherapy. Further study is needed to compare efficacy of different treatment strategies for this disease.
Clinical • Retrospective data • Journal
|
SSTR (Somatostatin Receptor)
|
temozolomide
21d
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. (PubMed, Cancer Med)
P2/3; We conclude that impaired EPR to pET is suitable to identify cases with primary endocrine resistance in early luminal breast cancer and that TP53-mutated luminal cancers might not be sufficiently treated by endocrine therapy alone.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR1 (Fibroblast growth factor receptor 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • GATA3 (GATA binding protein 3)
|
TP53 mutation • HER-2 amplification • HER-2 mutation • FGFR1 amplification • CCND1 amplification • ER expression
|
Oncotype DX Breast Recurrence Score®Test
|
tamoxifen
22d
Exosomal ANXA1 derived from thyroid cancer cells is associated with malignant transformation of human thyroid follicular epithelial cells by promoting cell proliferation. (PubMed, Int J Oncol)
Collectively, these findings indicated that SW579 cell‑derived exosomal ANXA1 promoted thyroid cancer development and Nthy‑ori3‑1 cell malignant transformation. Therefore, these findings may aid in the development of effective treatment methods for thyroid cancer.
Journal
|
ANXA1 (Annexin A1)
|
ANXA1 expression
22d
Pituitary carcinoma: a case of dramatic response to immunotherapy (ipilimumab + nivolumab) after failure with temozolomide (SNO 2021)
Here we demonstrate the utility of immunotherapy in a single case report of PC. This treatment helped our patient survive well beyond the expected median life expectancy of this aggressive disease.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • MGMT (6-O-methylguanine-DNA methyltransferase) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
|
TP53 mutation • MLH1 mutation
|
MSK-IMPACT
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide
22d
Recurrent meningioma with 1p/22q somatic mutation of GNAS: a case report (SNO 2021)
According to the molecular diagnosis results, the precise treatment plan was determined: concurrent chemoradiotherapy, followed by anti-VEGF-targeted drugs combined with temozolomide for 2 months...CONCLUSION This case is the first to report a meningioma with pituitary tumor driver gene GNAS mutation, which is more prone to recurrence due to the combination of 1P / 22Q chromosome mutation. Molecular diagnosis can guide precise treatment to benefit patients.
Clinical
|
GNAS (GNAS Complex Locus)
|
VEGFA expression
|
temozolomide
22d
Clinical utility of somatostatin receptor PET imaging biomarkers for characterization of meningioma among incidental CNS lesions (SNO 2021)
Prior cranial radiation or use of a somatostatin mimetic did not affect quantitative radiographic measures in lesion characterization, and MRI-based tumor size was similar across groups. CONCLUSION The continued development of SSTR-based imaging biomarker signatures across incidental CNS lesion subtypes will further define the role of this imaging modality in the clinical diagnosis and management of presumed meningiomas.
Clinical
|
SSTR (Somatostatin Receptor)
22d
Complete Response to Selpercatinib in a Patient with Recurrent Glioblastoma and RET Amplification (SNO 2021)
Larger biomarker-enriched studies are needed to confirm the results of this case report. However, given the rare incidence of RET alterations in GBM, findings from this report can help guide and support optimal treatment strategies for patients with RET-altered GBM.
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
22d
Multi-institution Retrospective Experience with Lenvatinib for Progressive Malignant Glioma (SNO 2021)
Despite treatment with radiation and temozolomide chemotherapy, malignant gliomas inevitably recur after treatment and have poor prognosis. Clincal Benefit Rate (PR+SD) to Lenvatinib in recurrent disease was 57%, with 29% Partial Responses and 29% Stable Disease as best radiographic response. This retrospective cohort supports further evaluation of the efficacy of Lenvatinib in recurrent malignant glioma in a clinical trial.
Retrospective data
|
FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • MGMT (6-O-methylguanine-DNA methyltransferase) • FLT1 (Fms-related tyrosine kinase 1)
|
temozolomide • lenvatinib
22d
Immunohistochemical assessment of membranous somatostatin type 2A receptor (SST2A) expression across high-risk pediatric central nervous system (CNS) tumors (SNO 2021)
CONCLUSIONS High membranous SST2A expression was demonstrated in medulloblastoma, meningioma, and some rarer embryonal tumors with potential diagnostic, biologic, and therapeutic implications. Somatostatin receptor-targeted therapy such as 177 Lu-DOTATATE deserves further investigation in these highly SST2A-expressing pediatric CNS tumors.
Clinical
|
SSTR (Somatostatin Receptor)
|
Lutathera (lutetium Lu 177 dotatate)
22d
Assessment of Y-H2AX and 53Bp1 Foci in peripheral Blood Lymphocytes to predict subclinical Hematoxicity and Response in Somatostatin Receptor-Targetad Radionuclide Therapy for Advanced Gastroenter. (NCRI 2021)
Y-H2AX and 53Bp1 foci formation were evaluated in peripheral blood lymphocytes (PBLs) at baseline+1h and +24h after administration of 7.4 GBq (177 lu) LU-DoTA-TATE PET/CT before enrollement and after 2 cycles of PRRT accourding to the volumetric modification of RECIST.1, Results DSB Marker kinetics were heterogenous among patients...DSB Marker kinetics were heterogenous among patients subclinical hematotoxicity was associated with Y-H2AX and 53BP1 Foci formation (e.g.change inplatelete count vs change in Y-H2Ax cells between baseline and +1h (r=-0.6080,P=0.0045) patient showing early developing of new Metatases had less Y-H2AX (p=0.0289) and demnstrated a distinct kinetic pattern. with an absence of DSB marker decrease art +24h (Y-H2AX:P=0.0025:53BP1:p=0.0008) Assessment of Y-H2AX and 53BP1 foci formation in PBLS of patients receiving radioliement Therapy.
SSTR (Somatostatin Receptor) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
Lutathera (lutetium Lu 177 dotatate)
22d
Longitudinal Copy Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis and Follow-Up. (PubMed, Clin Cancer Res)
Sequential genome-wide profiling of plasma cfDNA is a novel, non-invasive biomarker with high specificity for diagnosis, prognosis and follow-up in metastatic NENs.
Journal
|
CHGA (Chromogranin A)
23d
RHAMM-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment. (PubMed, Mol Ther Oncolytics)
Together, these findings indicate that the RHAMM-targeting nanotherapy serves as a promising drug delivery system for PNET and possibly other malignancies with upregulated RHAMM. The combination of siBcl-xL and KLA peptide can be a therapy for PNET treatment.
Journal
|
BCL2L1 (BCL2-like 1)
23d
A novel Lynch syndrome pedigree bearing germ-line MSH2 missense mutation c.1808A>T (Asp603Val). (PubMed, Jpn J Clin Oncol)
Immunohistochemical analyses indicated that the expression of the MSH2 protein was decreased in the tumors, such as gastric cancer and neuroendocrine carcinoma, due to the missense mutation c.1808A>T. This study showed that the MSH2 missense mutation c.1808A>T (Asp603Val) is a likely pathogenic mutation and is responsible for typical Lynch syndrome-associated malignancies, including neuroendocrine carcinoma.
Journal
|
MSH2 (MutS Homolog 2)
|
MSH2 mutation
23d
Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer. (PubMed, Arch Endocrinol Metab)
Disease progression after pregnancy was limited and probably related to more aggressive disease and higher risk stratification at diagnosis. Still, mild disease progression may have occurred asymptomatically in some patients.
Journal
|
TG (Thyroglobulin)
23d
Diagnostic performance of noninvasive imaging modalities for localization of insulinoma: A meta-analysis. (PubMed, Eur J Radiol)
Results of this study indicate that PET/CT demonstrated superior performance than SPECT/CT, CT and MRI for the localization of insulinoma. GLP-1R based PET/CT manifested better diagnostic performance in comparison with SSTR based PET/CT imaging modality.
Retrospective data • Journal
|
SSTR (Somatostatin Receptor)
23d
iPRIME: Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors (clinicaltrials.gov)
P2, N=46, Recruiting, University of Chicago | Trial primary completion date: Sep 2021 --> Sep 2022
Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • docetaxel
23d
[VIRTUAL] [ 177Lu]Lu-DOTA-TATE as First-line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): the NETTER-2 Study (NANETS 2021)
BACKGROUND: The NETTER-1 study demonstrated that [177Lu]Lu-DOTA-TATE, a radioligand therapy selectively targeting somatostatin receptors (SSTRs), plus 30 mg octreotide long-acting release (LAR), provided significantly increased progression-free survival (PFS) compared with 60 mg octreotide LAR in patients with GEP-NET who previously progressed on octreotide (HR, 0.21 [95% CI, 0.13-0.33]). Study is in progress.
Clinical
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lutathera (lutetium Lu 177 dotatate) • Sandostatin LAR Depot (octreotide acetate)
23d
[VIRTUAL] Dose Selection for Paltusotine, a Once Daily Oral Nonpeptide, Somatostatin Receptor 2 Ligand, for the Treatment of Patients with Carcinoid Syndrome (CS) (NANETS 2021)
We propose a similar starting dose for paltusotine in CS as in acromegaly. This dosing range (40-80 mg once daily) is further supported by clinical experience with LA-SRL therapies in gastro-entero-pancreatic NETs for which the approved doses are the same as acromegaly. Therefore, we will evaluate in an exploratory trial a paltusotine dose range from 40 to 80 mg/day with the potential, if required, for up titration to higher doses.
Clinical
|
IGF1 (Insulin-like growth factor 1) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
paltusotine (CRN00808)
23d
[VIRTUAL] Succinate Dehydrogenase Pathogenic Variants are Not Associated with Noncanonical Cancers (NANETS 2021)
SDHx PVs were strongly associated with PCC/PGL, but not with increased risk of other canonical human cancers. Future population-based studies are required to confirm these findings.
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2) • SDHD (Succinate Dehydrogenase Complex Subunit D)
23d
[VIRTUAL] Differences in the Mutation of DAXX, ATRX, and MENIN in Pancreatic Neuroendocrine Tumors from Black and White Patients (NANETS 2021)
The significant difference in loss of MENIN in specimens from Black patients supports the hypothesis that differential epigenetic modulation may be occurring in pNETs arising in this population.
Clinical
|
ATRX (ATRX Chromatin Remodeler) • DAXX (Death-domain associated protein)
|
ATRX mutation
23d
[VIRTUAL] Multifocality Is Not Associated with Worse Survival in Sporadic Pancreatic Neuroendocrine Tumors (NANETS 2021)
Multifocal sporadic pNETs are rare and multifocality is not associated with worse survival or increased recurrence risk. Hereditary cancer syndromes should be carefully ruled out in patients with multifocal tumors. Patients with multifocal sporadic pNETs can likely be safely managed with a combination of resection and observation as indicated for each tumor.
NF1 (Neurofibromin 1)
23d
[VIRTUAL] A Case of G3-WD Gastric Carcinoid Tumor in a MEN1 Patient with Discrepant Treatment Response to PRRT in Primary and Nodal Disease Sites (NANETS 2021)
Prior to commencement of PRRT the patient has received Cisplatin + Etoposide, Carboplatin + Etoposide, Hepatic Embolization and SAS. Treatment response pattern in the primary and metastatic carcinoid tumor sites may be difficult to assess but certainly can alter the management. DOTATATE PET/MRI may help in patient selection and combining the treatment agents.
Clinical
|
NCAM1 (Neural cell adhesion molecule 1) • GAST (Gastrin 2) • SYP (Synaptophysin)
|
cisplatin • carboplatin • etoposide IV
23d
P1 data
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lutathera (lutetium Lu 177 dotatate) • peposertib (M3814)
23d
[VIRTUAL] ETCTN 10388: a Phase 1 Trial of Triapine and Lutetium 177 Dotatate in Welldifferentiated Somatostatin Receptorpositive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (NANETS 2021)
Ribonucleotide reductase (RNR) is the only enzyme responsible for conversion of ribonucleoside diphosphate to deoxyribonucleotide diphosphate (dNDP), the key building blocks for DNA synthesis. Radiation is a potent inducer of DNA double-strand breaks (DSBs), and RNR is the rate-limiting enzyme in the repair of DNA in this setting. Triapine is an inhibitor of RNR.
P1 data
|
SSTR (Somatostatin Receptor)
|
SSTR positive • SSTR Expression
|
Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)
23d
[VIRTUAL] A Phase II Trial to Evaluate the Safety and Dosimetry of [177Lu]Lu-DOTATATE in Adolescent Patients with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs) (NANETS 2021)
SSTR subtype-2 is overexpressed by GEP-NET and PPGL tumors; therefore, it is a relevant target for peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE... Study is in progress.
Clinical • P2 data
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lutathera (lutetium Lu 177 dotatate)
23d
[VIRTUAL] Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma (NANETS 2021)
Extra-thoracic high grade NEC are potentially molecularly distinct entities as compared to SCLC. Extrapolation of therapeutic strategies from SCLC to extra-thoracic HG-NEC might not be optimal. Large prospective studies are needed to refine our understanding of molecular differences between small cell vs large cell NEC and thoracic vs extra-thoracic HG-NEC.
Tumor Mutational Burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1)
|
TP53 mutation • TMB-H
23d
Retrospective data
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lutathera (lutetium Lu 177 dotatate)
23d
[VIRTUAL] Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase 3 SPINET study (NANETS 2021)
SPINET, the largest prospective study to date with a somatostatin analog in SSTR-positive BP_NETs, suggests LAN 120 mg could be an appropriate treatment option, especially for TC. This study is funded by Ipsen.
Clinical • P3 data
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Somatuline Depot (lanreotide prolonged-release subcutaneous)
23d
[VIRTUAL] A Phase 2 Study of Surufatinib in Combination with Toripalimab in Patients with Advanced Neuroendocrine Carcinoma (NANETS 2021)
Surufatinib plus toripalimab demonstrated clinically meaningful anti-tumor activity, and is a potential treatment option for 2L treatment of NEC that should be further investigated. A randomized phase 3 study is initiated to further confirm the efficacy of this combination therapy in 2L NEC.
Clinical • P2 data • Combination therapy
|
PD-L1 (Programmed death ligand 1) • FGFR1 (Fibroblast growth factor receptor 1) • FLT1 (Fms-related tyrosine kinase 1) • CSF1R (Colony stimulating factor 1 receptor)
|
Tuoyi (toripalimab) • Sulanda (surufatinib)
23d
[VIRTUAL] Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects with Advanced Neuroendocrine Tumors (NANETS 2021)
Tidutamab was generally well tolerated with disease control in >50% of evaluable NET subjects. Additional studies in other tumors that express SSTR2 are warranted, and poor outcomes in subjects with higher PD(L)-1 expression suggest combinations with checkpoint inhibitors should be considered.
Clinical • PK/PD data • PD(L)-1 Biomarker • IO biomarker
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • CD4 (CD4 Molecule)
|
PD-1 expression • SSTR2 expression
|
tidutamab (XmAb18087)
23d
[VIRTUAL] Treatment Response and Clinical Outcomes of Neuroendocrine Neoplasms (NENs) Treated with Immune Checkpoint Inhibitors (ICIs): a Single Institution Experience (NANETS 2021)
We observed limited activity for ICI’s in NEN treatment, primarily restricted to a subset of PDNEC. PFS/OS findings were consistent with historical data, reflecting the pathogenesis of distinct NEN subtypes.
Clinical • Clinical data • Checkpoint inhibition • IO biomarker
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • SMAD4 (SMAD family member 4) • CREBBP (CREB binding protein) • IRS2 (Insulin receptor substrate 2)
23d
[VIRTUAL] Interim analysis results of surufatinib in US patients with neuroendocrine tumors (NETs) (NANETS 2021)
65.6% of patients had received ≥ 3 prior lines of treatment; all patients previously received everolimus and/or sunitinib. Surufatinib has demonstrated antitumor activity in heavily pretreated US patients with progressive NETs with a manageable safety profile that is consistent with 2 completed phase 3 studies.
Clinical
|
FGFR1 (Fibroblast growth factor receptor 1) • FLT1 (Fms-related tyrosine kinase 1) • CSF1R (Colony stimulating factor 1 receptor)
|
Sutent (sunitinib) • everolimus • Sulanda (surufatinib)
23d
[VIRTUAL] Exploring Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) (NANETS 2021)
All patients were refractory to platinum etoposide in the first line setting. In the second line setting, patients with GEP-NECs treated with dual ICPIs (ipilimumab and nivolumab) experienced improved PFS and OS compared to patients treated with single agent ICPI or cytotoxic chemotherapy. These results need to be validated in future prospective studies.
Clinical • Real-world evidence • Tumor Mutational Burden • PD(L)-1 Biomarker
|
TMB (Tumor Mutational Burden)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • etoposide IV
23d
[VIRTUAL] Loss of MEN1 Function Inhibits DNA Repair Capability of Pancreatic Neuroendocrine Tumors after Radiation Exposure (NANETS 2021)
Lastly, PARP1 inhibition (10nM Talazoparib) significantly increased radiotoxicity in MEN1-KO-QGP1 cells when compared to wild type QGP1 cells, particularly at lower IR doses (p<0.01 to <0.001). MEN1 loss of function sensitizes PanNET cells to IR and influences DNA repair pathway choice by lowering BRCA2 expression and inhibiting HR. Combining IR with PARP inhibition may be beneficial in PanNET patients with somatic MEN1 mutations.
BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • MEN1 (Menin 1)
|
BRCA2 expression
|
Talzenna (talazoparib)
23d
[VIRTUAL] Treatment Response and Clinical Outcomes of Well-differentiated (WD) High-grade (HG) Neuroendocrine Tumors (NETs) to 177Lu-DOTATATE (NANETS 2021)
We observed a meaningful disease response of 71% during WD HG NET treatment with 177Lu-DOTATATE. In this heavily pre-treated population, more than half of patients received all four treatment cycles. Treatment-related toxicities were largely bone-marrow related.
Clinical • Clinical data
|
RB1 (RB Transcriptional Corepressor 1) • SSTR (Somatostatin Receptor) • DAXX (Death-domain associated protein) • MEN1 (Menin 1)
|
SSTR positive
|
MSK-IMPACT
|
Lutathera (lutetium Lu 177 dotatate)
23d
[VIRTUAL] RNA-sequencing Identifies Unique Molecular Features of Duodenal Neuroendocrine Tumors (NANETS 2021)
Compared to normal tissue, DNETs have upregulation of PNET transcription factors ISL1 and PAX6. Although NETs from several sites share common differentially expressed genes, DNETs have distinct gene expression and are not more similar to either PNETs or SBNETs.
SPINK1 (Serine peptidase inhibitor, kazal type 1)
23d
[VIRTUAL] The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 Results (NANETS 2021)
PEN-221 appears well tolerated at 8.8 mg/m2 q 3 weeks and has demonstrated efficacy exceeding its clinical efficacy goals with a CBR of 88.5% and a mPFS of 9 months.
Clinical • P2 data
|
ALK (Anaplastic lymphoma kinase) • SSTR2 (Somatostatin Receptor 2)
|
nendratareotide uzatansine (PEN-221)
23d
[VIRTUAL] Establishment of Two Patient-derived Neuroendocrine Carcinoma Spheroid and Xenograft Models for Drug Testing (NANETS 2021)
The NEC913 and NEC1452 PDS lines are useful pre-clinical models for the study of neuroendocrine carcinoma. NEC913 expresses many NEC markers and maintains the histologic morphology of the original patient tumor. NEC1452 expresses few NEC markers.
Preclinical
|
TP53 (Tumor protein P53) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • CHGA (Chromogranin A) • SYP (Synaptophysin)
|
TP53 expression • CXCR4 expression
23d
[VIRTUAL] Safety and Effectiveness of 177LuSatoreotide Tetraxetan in Patients with Progressive Neuroendocrine Tumors (NETs): Interim Analysis of a Phase I/II Study (NANETS 2021)
These preliminary data, reporting an acceptable safety profile and a high DCR, are promising and support a potential role for 177Lu-satoreotide tetraxetan in treating advanced NETs.
Clinical • P1/2 data
|
SSTR (Somatostatin Receptor)
|
SOMther (lutetium-177 DOTA satoreotide)
23d
[VIRTUAL] Compose: Pivotal Phase III Trial of 177LuEdotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuroendocrine Tumors (NANETS 2021)
Current standard therapies for the subset of well-differentiated high grade 2 and grade 3 GEP-NETs include cytoreductive procedures, somatostatin analogues, molecular targeted therapies (everolimus or sunitinib), chemotherapy and peptide receptor radionuclide therapy (PRRT), with no specified sequence of use... It is expected that COMPOSE will increase treatment options for patients with well-differentiated high grade 2 and grade 3 GEP-NETs, including for first-line therapy.
P3 data
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR2 expression • SSTR Expression
|
5-fluorouracil • Sutent (sunitinib) • everolimus • leucovorin calcium • Solucin (177Lu-edotreotide)
23d
[VIRTUAL] Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience (NANETS 2021)
Six patients (1 woman and 5 men, mean±SD: 59.7±11.7-year-old) with progressive, somatostatin receptor (SSR)-expressing PPGL (4 paraganglioma, 2 pheochromocytoma) were treated with 177Lu-DOTATATE... Our preliminary data show overall good results for patients with progressive PPGL treated with PRRT: high DC of 80%, ORR of 33% and PFS of 83% at 11-month follow-up. Hematotoxicity included grade 3 transient neutropenia and lymphopenia (33.3%).
Clinical
|
SSTR (Somatostatin Receptor)
|
Lutathera (lutetium Lu 177 dotatate)
23d
[VIRTUAL] Blood-based Genomic Assessment of Clinical Efficacy and Toxicity of 177LuDOTATATE of Neuroendocrine Tumors (NANETS 2021)
NETest decreased during 177Lu-DOTATATE in responders, increased in non-responders and can be used as an early monitor of response. PPQ predicted response in 97%. RAD-TOX correlated with hematological toxicity and pre-PRRT scores predicted toxicity with 75% accuracy.
Clinical
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
NETest®
|
Lutathera (lutetium Lu 177 dotatate)
23d
[VIRTUAL] Novel Fusion Gene UBTF-MAML3 Drives Tumorigenesis in Neuroendocrine Tumor Cells (NANETS 2021)
Overexpressed UBTF-MAML3 fusion gene increased invasion and colony formation, suggesting it is a driver of tumorigenesis and metastatic disease. The mechanism of action is still unknown.
FUS (FUS RNA Binding Protein)
23d
[VIRTUAL] Variability of Somatostatin Receptor Type 2 Immunohistochemical Staining Patterns Among Gastroenteropancreatic Neuroendocrine Tumors (NANETS 2021)
Our study found an association between high SSTR2 expression and GEP-NETs of pancreatic origin. Tumors with a lower SSTR2 expression were likely to be metastatic than primary tumors.
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR2 expression • SSTR2 positive
23d
[VIRTUAL] Genomic Profiling of Responders and Nonresponders to Checkpoint Inhibition in Neuroendocrine Carcinoma (NANETS 2021)
In this small series, the small cell lung cancer-like genomic signature of TP53and RB1mutations was significantly more frequent in responders to ICI compared to non-responders. Further study is warranted to determine whether the presence of having simultaneous TP53and RB1mutations predicts response to ICI in NEC.
Checkpoint inhibition • IO biomarker
|
TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
TP53 mutation • RB1 mutation + TP53 mutation
23d
[VIRTUAL] Cd36 mediated metabolic reprogramming in cancer stem cells contributes to drug resistance to mTOR inhibition in pancreatic neuroendocrine tumors (NANETS 2021)
Current therapeutic efficacy is limited, accompanied by resistance to targeted chemotherapies, such as everolimus (a derivative molecule from rapamycin, an mTOR inhibitor), in which cancer stem cells (CSCs) play a critical role...Furthermore, tumor invasion and migration assays were performed in the control and drug-resistant cells with treatment of palmitic acids (long-chain fatty acids) and etomoxir (inhibitor of fatty acids oxidation)... CD36-mediated fatty acid metabolism is essential for maintaining stemness features, which may contribute to therapeutic resistance and metastatic relapse in PNETs.
CD36 (thrombospondin receptor)
|
everolimus • sirolimus • etomoxir (MIQ-001)
23d
[VIRTUAL] Rabl6a-myc signaling promotes pancreatic neuroendocrine tumor cell proliferation and survival (NANETS 2021)
Tumor suppressive effects of inhibitors targeting Myc (JQ1, CPI203) and CDK4/6 (palbociclib), individually or combined, were measured in pNET cells and xenograft tumors. Our findings demonstrate RABL6A is a new essential regulator of Myc signaling in pNETs whose expression is required for responsiveness to bromodomain inhibitors. Combined targeting of Myc and CDK4/6 kinases enhances RB1 tumor suppressor activity and may be a useful approach for treating pNETs that harbor activated Myc and CDK4/6.
ER (Estrogen receptor) • RB1 (RB Transcriptional Corepressor 1)
|
MYC expression • ER expression
|
Ibrance (palbociclib) • JQ-1 • CPI-203
23d
[VIRTUAL] Succinate accumulation is not sufficient for tumorigenesis in mouse chromaffin cells but dual loss of SDHB and NF1 yields SDHx-like pheochromocytomas (NANETS 2021)
Contrary to the prevailing oncometabolite model, succinate accumulation and 2-OG-dependent dioxygenase inhibition are insufficient for mouse pheochromocytoma tumorigenesis, which requires additional growthregulatory pathway dysregulation. This work describes the first mouse model for SDHx pheochromocytoma which recapitulates most essential aspects of the human disease.
Preclinical
|
NF1 (Neurofibromin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
23d
[VIRTUAL] Sex-specific transcriptional differences and loss of gene imprinting in pancreatic neuroendocrine tumors (NANETS 2021)
These results depict an emergence of sex-associated genetic and epigenetic dysregulations in PNETs.
IGF2 (Insulin-like growth factor 2) • RASSF7 (Ras Association Domain Family Member 7)
27d
Low expression of TFF3 in papillary thyroid carcinoma may correlate with poor prognosis but high immune cell infiltration. (PubMed, Future Oncol)
TFF3 and FCGBP are coexpressed in PTC, and patients with lower gene expression had worse disease-free survival but higher immune cell infiltration. TFF3 was significantly underexpressed and may function with FCGBP synergistically in PTC.
Journal
|
TFF3 (Trefoil factor 3)
|
TFF3 expression
27d
Update 2021: Management of Small Cell Lung Cancer. (PubMed, Lung)
While modest improvements in survival have been made especially in the metastatic setting with chemo-immunotherapy, further research in understanding the biology of SCLC is warranted to develop biomarker-driven therapeutic strategies and combinational approaches for this aggressive disease.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD4 (CD4 Molecule)
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • etoposide IV • topotecan • Cosela (trilaciclib) • Zepzelca (lurbinectedin)
27d
Geographical Variation in the profile of RET Variants in Patients with Medullary Thyroid Cancer: A Comprehensive Review. (PubMed, Eur J Endocrinol)
Unfortunately, after almost three decades after the causative role of the germline RET variants have been reported in hereditary MTC, comprehensive genotyping data remain limited to a few countries. The heterogeneity of RET variants justifies the need for a global effort to describe epidemiological data of families with MEN2 to further understand the genetic background and environmental circumstances that affect disease presentation.
Clinical • Review • Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
27d
TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change. (PubMed, Cell Rep)
Mutant TIAM1 with reduced Nur77 binding fails to suppress apoptosis triggered by TIAM1 depletion. In conclusion, TIAM1-RAC1 signaling promotes SCLC cell survival via Nur77 nuclear sequestration.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • RAC1 (Rac Family Small GTPase 1) • TIAM1 (TIAM Rac1 Associated GEF 1)
27d
Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours. (PubMed, BMJ Open Gastroenterol)
Stromal-epithelial interactions induce proinflammatory cytokines that promote Brunner's gland reprogramming.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • CHGA (Chromogranin A) • MEN1 (Menin 1) • SYP (Synaptophysin)
28d
SDHB variant type impacts phenotype and malignancy in pheochromocytoma-paraganglioma. (PubMed, J Med Genet)
SDHB truncating variants convey an elevated risk for development of both PPGL and malignancy compared with missense variants. These results further support earlier robust associations between truncating variants and PPGL, and also suggest that the two variant types differ in their impact on complex II function, with PPGL/HNPGL tissues displaying differing sensitivities to changes in complex II function.
Journal
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHD (Succinate Dehydrogenase Complex Subunit D)
28d
Anticancer Effects of Ursi Fel Extract and Its Active Compound, Ursodeoxycholic Acid, in FRO Anaplastic Thyroid Cancer Cells. (PubMed, Molecules)
Furthermore, UF extract and UDCA treatment stimulated Akt phosphorylation and inhibited mTOR phosphorylation in these cells. These results indicate that UF extract and UDCA exert anticancer properties in FRO cells by inducing apoptosis and inhibiting angiogenesis via regulating the Akt/mTOR signaling pathway.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • SIRT1 (Sirtuin 1)
|
BCL2 expression • BAX expression
|
ursodeoxycholic acid
28d
Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. (PubMed, J Pathol)
ALT, transcription factor protein expression, and possibly DNA methylation can be assessed in endoscopic ultrasound-guided tumor biopsies. Prospective studies focusing on cell-of-origin and epigenetic profile driven decision-making prior to surgery are likely to be routinely implemented into clinical practice in the near future.
Clinical • Review • Journal
|
ATRX (ATRX Chromatin Remodeler) • DAXX (Death-domain associated protein)
28d
Genetic spectrum in a Canadian cohort of apparently sporadic pheochromocytomas and paragangliomas: New data on multigene panel retesting over time. (PubMed, Clin Endocrinol (Oxf))
The prevalence of germline mutations in our cohort of patients with apparently sporadic PPGLs was 26.2%. Genetic re-evaluation over time using multigene sequencing by NGS assay in a subgroup of patients leads to an increase in the detection of mutations.
Journal
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHD (Succinate Dehydrogenase Complex Subunit D)
28d
Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells. (PubMed, J Mol Cell Biol)
Moreover, the TRPV1 antagonist CPZ, the calcium chelator BAPTA, and the PKA inhibitor H-89 effectively alleviated the re-differentiation exerted by CAP, demonstrating that CAP might improve radioiodine avidity through the activation of the TRPV1‒Ca2+/cAMP/PKA/CREB signaling pathway. In addition, our study indicated that CAP might trigger a novel cascade to re-differentiate ATC cells and provide unprecedented opportunities for radioiodine therapy in ATC, bypassing canonical TSH‒TSHR pathway.
Journal
|
NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8)
28d
Bile Acid Diarrhea in Adults and Adolescents. (PubMed, Neurogastroenterol Motil)
BAD has also been identified as a co-factor contributing to persistent diarrhea in other diseases in remission including inflammatory bowel disease, microscopic colitis, celiac disease, and neuroendocrine tumors. In summary, advances in diagnosis of BAD provide opportunities for generalists and pediatric and adult gastroenterologists to provide targeted treatment for BAD presenting as chronic non-bloody diarrhea.
Clinical • Review • Journal
|
FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4)
28d
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm. (PubMed, J Otolaryngol Head Neck Surg)
Our findings demonstrate an association between a BRAF V600E mutation and aggressive features in PTMC (≤ 1 cm) and small PTC (1-1.5 cm). Therefore, determining the molecular status of these thyroid nodules for the presence of BRAF V600E can help guide patient management.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
28d
Immunohistochemical Expression of Choline Acetyltransferase and Catecholamine-Synthesizing Enzymes in Head-and-Neck and Thoracoabdominal Paragangliomas and Pheochromocytomas. (PubMed, Endocr Pathol)
Immunohistochemistry of ChAT could be greatly useful for pathologic diagnosis of HNPGL. Whether measurement of acetylcholine levels in the blood or urine could be a tumor marker of HNPGLs should be investigated soon.
Journal
|
CHGA (Chromogranin A) • SYP (Synaptophysin)
28d
Lactate Dehydrogenase A or B Knockdown Reduces Lactate Production and Inhibits Breast Cancer Cell Motility in vitro. (PubMed, Front Pharmacol)
Also, LDH-A or -B knockdown reduced ERK 1/2 phosphorylation. Enhanced cell motility in endocrine resistant breast cancer cells is at least in part mediated by enhanced extracellular lactate levels, and LDH inhibition might be a promising therapeutic target to inhibit cancer cell motility.
Preclinical • Journal
|
LDHA (Lactate dehydrogenase A) • LDHB (L-lactate dehydrogenase B chain) • CDH1 (Cadherin 1)
|
CDH1 expression
28d
The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. (PubMed, Front Endocrinol (Lausanne))
Furthermore, aggressive pituitary tumors demonstrated significantly higher levels of CD80 and CD86 compared to non-aggressive tumors. Our results establish a rationale for studying a potential role for immune checkpoint inhibition therapy in the treatment of pituitary adenomas.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CD86 (CD86 Molecule)
28d
Overexpression of PAX8-AS1 Inhibits Malignant Phenotypes of Papillary Thyroid Carcinoma Cells via miR-96-5p/PKN2 Axis. (PubMed, Int J Endocrinol)
Importantly, according to the rescue experiments, PKN2 silencing partially reversed the inhibitory effects of PAX8-AS1 expression on PTC cell proliferation and apoptosis. We found that the PAX8-AS1/miR-96-5p/PKN2 axis was closely related to the progression of PTC, which could be a potential target for treating PTC patients.
Journal
|
MIR96 (MicroRNA 96) • PAX8 (Paired box 8)
28d
Protein profiling reveals potential isomiR-associated cross-talks among RNAs in cholangiocarcinoma. (PubMed, Comput Struct Biotechnol J)
Simultaneously, RAB11FIP1 and miR-194-5p were also detected other related lncRNAs (FBXL19-AS1, SNHG1 and PVT1) that may be crucial in coding-non-coding RNA regulatory network. Our results show that diverse isomiRs with sequence and expression heterogeneities contribute to ceRNA regulatory network that may have crucial roles in CCA, which will expand our understanding of interactions among diverse RNAs and their contributions in cancer development.
Journal
|
MIR142 (MicroRNA 142) • MIR194 (MicroRNA 194) • PVT1 (Pvt1 Oncogene)
28d
PD-L1, Mismatch Repair Protein, and NTRK Immunohistochemical Expression in Cervical Small Cell Neuroendocrine Carcinoma. (PubMed, Front Oncol)
Cervical SCNC is a MMR-stable tumor and lacks NTRK gene fusion. IHC isn't a reliable method in the detection of NTRK gene fusion in cervical SCNC.
Journal • Mismatch repair • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • MSI-H/dMMR • PD-L1 negative • NTRK fusion • NTRK positive
28d
Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib. (PubMed, Front Oncol)
Cabozantinib had a direct effect on DCs by the down-modulation of β-catenin and change in migratory and costimulatory phenotype of the DCs. These results may suggest possible immunomodulatory effects induced by Cabozantinib that could be exploited to optimize patient-tailored immunotherapeutic treatments.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
Cabometyx (cabozantinib tablet)
29d
NKX2-1 re-expression induces cell death through apoptosis and necrosis in dedifferentiated thyroid carcinoma cells. (PubMed, PLoS One)
After suppressing these genes by siRNA, cell death, apoptosis, and necrosis decreased in RGS4 knockdown cells. These findings demonstrated that cell death was induced via apoptosis and necrosis by NKX2-1 re-expression and involves RGS4.
Journal
|
NKX2-1 (NK2 Homeobox 1) • ARG2 (Arginase 2)
|
NKX2-1 expression
29d
Clinical • New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
Tyvyt (sintilimab) • Epidaza (chidamide)
1m
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, Ascentage Pharma Group Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
BCL2L2 (BCL2 Like 2)
|
pelcitoclax (APG-1252)
1m
Clinical • New P1 trial
|
SSTR (Somatostatin Receptor)
|
SSTR positive
1m
Clinicopathological features and molecular characteristics of tall cell and hobnail variants of papillary thyroid carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
TCV-PTC and HV-PTC, as highly-aggressive variants of PTC, show more aggressive biologic behavior (more lymph node metastasis, external thyroid invasion and recurrences) than the classical and follicular variants of PTC. Coexisting BRAF and TERT promoter mutations may be associated with invasive biologic behavior.
Clinical • Journal
|
BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
|
BRAF V600E • BRAF V600 • TERT promoter mutation • TERT mutation
1m
Clinicopathological characteristics of SMARCB1(INI1)-deficient sinonasal carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
They are negative for INI1 IHC staining, and FISH demonstrates INI1 gene deletion. The clinical prognosis is still unclear, further studies on its biologic behavior and treatment methods are warranted.
Clinical • Journal
|
SMARCB1 • NCAM1 (Neural cell adhesion molecule 1) • TP63 (Tumor protein 63)
1m
Prognostic value of whole-body PET volumetric parameters extracted from Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumors. (PubMed, J Nucl Med)
In multivariate analysis, SRETVwb (P = 0.005) was the only independent predictor of TTP regardless of histopathologic grade and TNM staging. According to our results, SRETVwb and TLSREwb extracted from Ga-DOTATOC-PET/CT could predict TTP/OS and might have an important clinical utility in the management of in patients with WD-NETs.
Journal
|
SSTR (Somatostatin Receptor)
|
SSTR Expression
1m
Persistent hypercalcemia with similar familial Hypocalciuric hypercalcemia features: a case report and literature review. (PubMed, BMC Endocr Disord)
We presented a patient with FHH phenotype whose common genetic tests were negative. Further research is needed to ascertain other causes leading to similar manifestations.
Clinical • Review • Journal
|
GNA11 (G Protein Subunit Alpha 11)
1m
Bone metastasis from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); a case report. (PubMed, BMC Endocr Disord)
This case presentation reminds us to be alert to the rare occurrence of distant metastasis in NIFTP and the need for a case by case analysis and continuing post-operative follow-up for detection of residual or recurrent disease.
Clinical • Journal
|
TG (Thyroglobulin)
1m
Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer. (PubMed, J Clin Invest)
In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients.
Clinical • Journal
|
NTRK (Neurotrophic receptor tyrosine kinase)
1m
Prognostic and Immune-Infiltrate Significance of miR-222-3p and Its Target Genes in Thyroid Cancer. (PubMed, Front Genet)
Finally, CD109 expression was closely correlated with immune cells, especially B cells and CD4 T cells. The miR-222-3p and its critical target genes could be promising biomarkers for the prognosis of THCA and may emerge as key regulators of immune infiltration in THCA.
Journal
|
CD4 (CD4 Molecule)
1m
Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors. (PubMed, Front Oncol)
The study shows an improved survival rate, increased activation of immune system pathways, and an enrichment of EGFR alterations in female patients of our cohort. Enhancement of the immune response in female cancer patients is a phenomenon that should be further explored to improve the efficacy of immunotherapy.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
1m
Circ_0039411 promotes papillary thyroid carcinoma development through mediating the miR-423-5p/SOX4 signaling. (PubMed, Int J Biol Markers)
Circ_0039411 promoted the malignant behaviors of papillary thyroid carcinoma cells partly depending on the regulation of the miR-423-5p/SOX4 axis.
Journal
|
YBX1 (Y-Box Binding Protein 1) • SOX4 (SRY-Box Transcription Factor 4)
1m
Downregulation of miR-216a-5p and miR-652-3p is associated with growth and invasion by targeting JAK2 and PRRX1 in GH-producing pituitary tumours. (PubMed, J Mol Endocrinol)
The direct target genes of miR-216a-5p and miR-652-3p were Jak2 and Prrx1, respectively, which were downregulated in GH3 cells transfected with mimics and in serial pituitary gland tissues, including hyperplasic tissues and tumours of acromegalic animal models and pituitary tumour tissues of acromegalic patients. Downregulated miR-216a-5p and miR-652-3p expression may contribute to tumour progression by targeting JAK2 and PRRX1 on GH-producing pituitary tumours.
Journal
|
JAK2 (Janus kinase 2) • MIR216A (MicroRNA 216a) • PRRX1 (Paired Related Homeobox 1)
1m
Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes. (PubMed, Horm Metab Res)
The most important factors that determine long-term prognosis of ACC are the disease stage at diagnosis, the Weiss score, and the Ki67 index. Immunohistochemical markers such as melan A could also serve as prognostic factors.
Journal
|
TP53 (Tumor protein P53) • VIM (Vimentin) • MLANA (Melan-A) • SYP (Synaptophysin)
1m
Solid Thyroid Follicular Nodules With Longitudinal Nuclear Grooves: Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 18 Cases. (PubMed, Arch Pathol Lab Med)
Clinical follow-up ranging from 18 to 72 months (median, 43.7 months) did not disclose any evidence of recurrence or metastases. We interpret these lesions as low-grade, indolent follicular proliferations that need to be distinguished from papillary thyroid carcinoma, follicular adenoma, and noninvasive follicular thyroid neoplasms with papillary-like nuclear features.
Clinical • Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • KRT19 (Keratin 19)
|
NRAS mutation • HRAS mutation
1m
Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis: a clinicopathological study of 1,139 cases with long-term follow-up. (PubMed, Endocr J)
Our findings indicate that low PDIA3 expression is related to poor clinical outcome in PTC patients, and that PDIA3 may potentially be a novel ancillary biomarker. Further clarification of the biological role of PDIA3 in PTC is warranted for the future clinical application.
Clinical • Journal
|
PDIA3 (Protein Disulfide Isomerase Family A Member 3)
1m
New approach of prediction of recurrence in thyroid cancer patients using machine learning. (PubMed, Medicine (Baltimore))
Three rules that could predict recurrence were identified, with postoperative thyroglobulin level being the most powerful variable that correlated with recurrence. The rules identified in our study, when applied to the 161 cases for validation, were able to predict 71.4% (10 of 14) of the recurrences.Our study highlights that inductive logic programming could have a useful application in predicting recurrence among thyroid patients.
Clinical • Journal
|
BRAF (B-raf proto-oncogene) • TG (Thyroglobulin)
|
BRAF mutation
1m
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. (PubMed, Drugs Today (Barc))
In May 2020, the U.S. Food and Drug Administration (FDA) approved a novel specific RET inhibitor for use in some subtypes of lung and thyroid cancers with RET alterations. In this review, we summarize the mechanism of action, pharmaceutical properties and clinical data of selpercatinib, and share some of our perspectives.
Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
|
Retevmo (selpercatinib)
1m
Current update on imaging for pancreatic neuroendocrine neoplasms. (PubMed, World J Clin Oncol)
These new techniques can also play a direct role in optimizing the selection of treatment for individuals and predicting tumor response based on somatostatin receptor expression. In addition, emerging methods of radiomics such as texture analysis may be a potential tool for staging and outcome prediction in panNEN, however further investigation is required before clinical implementation.
Review • Journal
|
SSTR (Somatostatin Receptor)
|
SSTR Expression
1m
Measurement of thyroglobulin level in lateral neck lymph node fine needle aspiration washout fluid in papillary thyroid cancer. (PubMed, Gland Surg)
Diagnostic accuracy is higher using a 20 ng/mL FNA-Tg cutoff level. Tg ratio is also valuable and FNA-Tg combined with Tg ratio shows promise.
Journal
|
TG (Thyroglobulin)
1m
Development of a nutritional index to evaluate the effectiveness of total parenteral nutrition during the early postoperative period after pancreaticoduodenectomy. (PubMed, Gland Surg)
Based on CRP, and muscle density results, muscle, visceral and subcutaneous fat masses did not change after PD. In order to evaluate the nutritional status accurately after the hepato-biliary radical surgery, we suggest the muscle and fat mass measurement that can adjust the degree of inflammation during the early postoperative period.
Journal
|
CRP (C-reactive protein)
1m
Analysis of Prognostic Alternative Splicing Reveals the Landscape of Immune Microenvironment in Thyroid Cancer. (PubMed, Front Oncol)
Furthermore, there was an inextricable correlation between immune cell infiltration, immune checkpoint proteins, and AS events. This study will provide a basis for THCA immunotherapy in the future.
Journal • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
1m
Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. (PubMed, World J Clin Cases)
Finally, the importance of proangiogenic factors (platelet-derived growth factor, vascular endothelial growth factor, fibroblastic growth factor, angiopoietin, and semaphorins) in the progression of NET has been determined. Using the combination of biomarkers and imaging methods allows early evaluation of the appropriateness of treatment and response to treatment.
Review • Journal
|
SSTR (Somatostatin Receptor)
1m
Large Primary Neuroendocrine Tumor of the Liver in a 57-year-Old Female Presenting With MSSA Bacteremia. (PubMed, Am Surg)
Immunohistochemistry demonstrated positive staining for pancytokeratin, synaptophysin, chromogranin, and TTF-1, consistent with undifferentiated NET. While rare, NETs can originate from a variety of organs outside the gastrointestinal and bronchopulmonary tract, including the liver.
Journal
|
NKX2-1 (NK2 Homeobox 1) • SYP (Synaptophysin)
1m
BRAF V600E mutation in papillary thyroid carcinoma: it's relation to clinical features and oncologic outcomes in a single cancer centre experience. (PubMed, Endocr Connect)
BRAF V600E mutation had no effect on loco-regional recurrence, distant metastasis, overall survival or disease-free survival. These findings may be attributed to geographic variations or reflect that BRAF V600E may only serve as an indicator of poor prognosis in high risk groups.
Clinical • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
1m
New Directions in Imaging Neuroendocrine Neoplasms. (PubMed, Curr Oncol Rep)
Targeting the glucagon-like peptide-1 receptor by exendin-4 has a high sensitivity in localizing insulinomas...Other new targets involve the fibroblast activation protein and the cholecystokinin-2 receptors, where the ligand minigastrin opens new possibilities for the management of medullary thyroid carcinoma. Molecular imaging is an emerging field that improves the management of NENs.
Review • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • SSTR (Somatostatin Receptor) • FAP (Fibroblast activation protein, alpha)
|
Byetta (exenatide)
1m
Analysis of the prognostic significance and potential mechanisms of lncRNAs associated with m6A methylation in papillary thyroid carcinoma. (PubMed, Int Immunopharmacol)
According to our research, we can regard m6A-related lncRNAs involved in the procession of PTC as a biomarker of progression-free survival for PTC patients, and pan-cancer.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
1m
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer (clinicaltrials.gov)
P2, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2020 --> Sep 2023 | Trial primary completion date: Nov 2020 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Zelboraf (vemurafenib)
1m
Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation-Positive Langerhans Cell Histiocytosis (ASH 2021)
Dabrafenib, with or without trametinib, demonstrated durable efficacy in pediatric pts with relapsed/refractory BRAF V600E mutation-positive LCH, with 90-100% of responses ongoing at 24 months. Treatment was associated with acceptable tolerability and manageable toxicities; the safety profile was consistent with what has been seen in other pediatric indications and in adult studies.
Clinical • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF mutation • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1m
Germline Biallelic Loss in MBD4 leading to Early Onset AML with Hyper-Mutator Genomic Signature (ASH 2021)
Genomic profiling of the normal and affected tissue identified germline bi-allelic loss of function mutation in MBD4 as initiator of methylation defect in key driver genes in tissue specific manner leading to carcinogenesis. This conserved path to mutagenesis is unique to this cancer predisposition syndrome and further biological studies are needed to fully understand the spectrum of cancers associated with this syndrome.
Tumor Mutational Burden
|
FLT3 (Fms-related tyrosine kinase 3) • TMB (Tumor Mutational Burden) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • MBD4 (Methyl-CpG Binding Domain 4, DNA Glycosylase)
|
TMB-H • DNMT3A mutation • NF2 mutation • MBD4 mutation • DNMT3A R882
1m
Nogo-a Pathway Contributes to Neural Injury and Pain in Sickle Cell Disease (ASH 2021)
Our data suggest that PEA and targeting NOGO-A pathway may prevent/reduce chronic and acute hyperalgesia in sickle mice. We speculate that interventions targeting NOGO-A pathway may prevent/reduce neuropathic pain and that PEA has the translational potential for the treatment of chronic and acute pain in SCD.
TNFA (Tumor Necrosis Factor-Alpha)
1m
Journal
|
BRAF (B-raf proto-oncogene) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1)
1m
Clinical and genomic analyses of neuroendocrine neoplasms of the breast. (PubMed, Mod Pathol)
The oncogenic/likely oncogenic mutations of NETs in PI3K pathway genes (50.0%, 18.2%; P < 0.001) and MAPK signaling pathway genes (83.3%, 18.2%; P = 0.035) affected higher proportions than those of NECs. In conclusion, this study provides certain clinical and molecular evidence supporting NENs as a distinct subtype of breast cancer and provides some potential molecular features for distinguishing NETs from NECs.
Clinical • Journal
|
KMT2C (Lysine Methyltransferase 2C) • PDE4DIP (Phosphodiesterase 4D Interacting Protein) • GATA3 (GATA binding protein 3)
|
Chr del(11q)
1m
The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options. (PubMed, Contemp Oncol (Pozn))
Responses to immune checkpoint inhibitors in mismatch repair-deficient/microsatellite instability-high tumours of other locations have shown promising results, and with the extended approval of the PD-1 receptor inhibitor pembrolizumab by the Food and Drug Administration, also anaplastic thyroid cancer (ATC) requires analysis for microsatellite instability (MSI) status...There are insufficient and heterogenous data concerning the predictive or prognostic value of mismatch repair-deficient/microsatellite instability status. Tumour molecular profiling is fundamental in ATC for predictive, prognostic, as well as therapeutic reasons, and analysis of MSI status is strongly suggested because a small subgroup show the MSI signature and might profit from recently approved targeted therapies.
Review • Journal • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
|
TP53 mutation • MSI-H/dMMR • NF1 mutation • MSH2 mutation • MLH3 mutation • PMS2 mutation
|
Keytruda (pembrolizumab)
1m
LncRNA NORAD promotes thyroid carcinoma progression by targeting miR-451. (PubMed, Eur Rev Med Pharmacol Sci)
Our results indicated that the cell migration and invasion were inhibited by knockdown of lncRNA NORAD or overexpression of miR-451, suggesting that the axis of lncRNA NORAD -miR-451- IL-6R was involved in the development of PTC.
Journal
|
IL6R (Interleukin 6 receptor) • NORAD (Non-Coding RNA Activated By DNA Damage)
|
IL6 expression • IL6R overexpression • miR-451 overexpression
1m
ANXA1 (Annexin A1) regulated by MYC (MYC proto-oncogene) promotes the growth of papillary thyroid carcinoma. (PubMed, Bioengineered)
ANXA1 may be regulated by MYC to promote the proliferation of PTC. MYC may regulate the expression of ANXA and thus affect the proliferation of PTC.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ANXA1 (Annexin A1)
|
MYC expression • ANXA1 overexpression
1m
BRAF hot spot mutation in thyroid carcinomas: first Moroccan experience from a single-institution retrospective study. (PubMed, Afr Health Sci)
Like international trends, Papillary Thyroid Carcinomas 'PTC' is more frequent than Follicular Thyroid Carcinomas 'FTC' and Anaplastic Thyroid Carcinomas 'ATC' (29 PTC, 7 FTC and 1 ATC). Our finding gives to the international community the first estimated incidence of this oncogene in Morocco showing that this prevalence falls within the range of international trends (30% to 90%) reported in distinct worldwide geographic regions.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
1m
A case of pancreatic neuroendocrine carcinoma with a favorable clinical response to pembrolizumab. (PubMed, Clin J Gastroenterol)
Although there is no established PanNEC therapy, those with MSI-high may respond favorably to pembrolizumab. Therefore, we should ascertain the MSI status of any PanNEC in routine practice.
Clinical • Journal
|
MSI (Microsatellite instability) • NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
1m
Insights into Mechanisms of Tumorigenesis in Neuroendocrine Neoplasms. (PubMed, Int J Mol Sci)
Furthermore, models of tumorigenesis based on composite interactions other than a linear progression of events are proposed, exemplified by the involvement in NEN tumorigenesis of genes regulating complex functions, such as MEN1 or DAXX. Although limited by interspecies differences, animal models have proved helpful for the more in-depth study of every facet of tumorigenesis, showing that the identification of driver mutations is only one of the many necessary steps and that other mechanisms are worth investigating.
Review • Journal
|
DAXX (Death-domain associated protein)
1m
How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations. (PubMed, J Mol Model)
Structural analysis further showed that the distribution of K758, D892, and N879 network had a detrimental effect on the binding of compound 1 to the L881V mutant. The obtained results may provide insight into the mechanism of overcoming resistance in the RET kinase.
Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
|
nintedanib
1m
A critical balance between Pax8 and the Hippo mediator TAZ determines sodium-iodide symporter NIS expression and function. (PubMed, Thyroid)
We demonstrate that the effects of TAZ are promoter specific, as it functions as a co-repressor of PAX8 to modulate Slc5a5 expression in thyroid follicular cells. Overall, our data place TAZ as an integrator of the different signaling pathways that control NIS expression, pointing to a role for TAZ in thyroid differentiation, and identifying the Hippo pathway as a relevant target to recover NIS levels in thyroid cancer cells.
Journal
|
YAP1 (Yes associated protein 1) • TGFB1 (Transforming Growth Factor Beta 1) • PAX8 (Paired box 8) • TG (Thyroglobulin)
1m
Gastroenteropancreatic neuroendocrine tumors (PubMed, Radiologe)
Treatment options include endoscopic or surgical resection, drug therapy for control of symptoms and proliferation, locoregional therapy and radionuclide therapy. Guidelines with algorithms for diagnostic workup and treatment are constantly updated.
Journal
|
SYP (Synaptophysin)
1m
Primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy: a case report. (PubMed, Surg Case Rep)
Due to the lack of availability of abundant quantities of relevant, high-quality data, there is no standard therapy for primary hepatic NECs. Selecting the most appropriate treatment for patients depending on several factors, such as the stage and differentiation of a tumor and a patient's performance status and clinical course, is consequently preferred. More cases need to be studied to establish the best treatment strategy for primary hepatic NEC.
Clinical • Journal
|
NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
|
carboplatin • etoposide IV
1m
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) (clinicaltrials.gov)
P2, N=213, Active, not recruiting, EpicentRx, Inc. | Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
cisplatin • carboplatin • gemcitabine • Abraxane (albumin-bound paclitaxel) • etoposide IV • irinotecan • pemetrexed • pegylated liposomal doxorubicin • vinorelbine tartrate • RRx-001
1m
ASYMPTOMATIC T LYMPHOPENIA IN A YOUNG ADULT WITH PTEN GENE MUTATION (ACAAI 2021)
Clinical presentations of these lymphopenic patients range from infection-free to having opportunistic infections including Pneumocystis . Patients with PTEN mutation should be monitored for immune defects, infections, and autoimmunity, with an allergist/immunologist involved in their long-term care.
Clinical
|
PTEN (Phosphatase and tensin homolog) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
PTEN mutation
1m
Antibody-Free Quantification of Serum Chromogranin A by Targeted Mass Spectrometry. (PubMed, Clin Chem)
Quantification of CgA by LC-MS/MS provides an analytically sensitive and reproducible alternative to commercially available immunoassays.
Journal
|
CHGA (Chromogranin A)
1m
80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53. (PubMed, Front Biosci (Landmark Ed))
In vivo studies have shown that tumor growth was positively correlated with MAP17 expression and negatively correlated with p53 expression. Our findings revealed that MAP17 exhibited carcinogenic effects through interacting with NUMB to reduce the stability of p53, demonstrating that MAP17 may serve as a potential prognostic biomarker for PTC treatment.
Journal
|
CDH1 (Cadherin 1) • PDZK1IP1 (PDZK1 interacting protein 1)
|
CDH1 expression • TP53 overexpression • PDZK1IP1 overexpression
1m
Estrogen Receptor β as a Possible Double-Edged Sword Molecule in Breast Cancer: A Mechanism of Alteration of Its Role by Exposure to Endocrine-Disrupting Chemicals. (PubMed, Biol Pharm Bull)
However, there is no consensus on the correlation between ERβ expression levels and clinical prognosis, which might be due to differences in exposed chemicals. Therefore, elucidating the exposure effects of EDCs can reveal the reason for inconsistent functional role of ERβ in ERα/β-positive breast cancer.
Journal
|
ER (Estrogen receptor)
1m
miR-381-3p attenuates doxorubicin resistance in human anaplastic thyroid carcinoma via targeting homeobox A9. (PubMed, Int J Exp Pathol)
Our results present a novel signalling axis miR-381-3p/HOXA9 that mediates DOX resistance in ATC. miR-381-3p and HOXA9 may be promising molecular targets for preventing ATC progression and drug resistance.
Journal
|
HOXA9 (Homeobox A9) • MIR381 (MicroRNA 381)
|
doxorubicin hydrochloride
1m
MicroRNA-424 alleviates neurocyte injury by targeting PDCD4 in a cellular model of cerebral ischemic stroke. (PubMed, Exp Ther Med)
Furthermore, overexpression of miR-424 regulated the expression of PDCD4, Bax, Bcl-2, phosphorylated-PI3K/AKT and caspase-3, which was restored after co-transfection with pcDNA3.1-PDCD4. Collectively, the results indicated that miR-424 regulated the progression of cerebral ischemic stroke in a cellular model by targeting PDCD4.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • BAX (BCL2-associated X protein) • MIR424 (MicroRNA 424)
|
BCL2 expression • BAX expression • miR-424 expression
1m
A Bibliometric Analysis of 34,692 Publications on Thyroid Cancer by Machine Learning: How Much Has Been Done in the Past Three Decades? (PubMed, Front Oncol)
Thyroidectomy, differential diagnosis, genomic analysis, active surveillance are the most concerning topics in TC researches. Although the BRAF-targeted therapy is under development with promising results, there is still an urgent need for conversions from basic studies to clinical practice.
Journal
|
BRAF (B-raf proto-oncogene)
1m
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer (clinicaltrials.gov)
P3, N=437, Active, not recruiting, Genzyme, a Sanofi Company | Trial completion date: Dec 2021 --> Dec 2022
Clinical • Trial completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
Caprelsa (vandetanib)
1m
Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. (PubMed, Endocrine)
Present data support the use of SSAs in ZES, considering that gastrinoma is mainly a well-differentiated low-grade tumor (G1 or G2), with a high expression of somatostatin receptors.
Clinical • Observational data • Journal
|
SSTR (Somatostatin Receptor) • GAST (Gastrin 2)
|
SSTR Expression
1m
Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study. (PubMed, Mol Biol Rep)
To conclude, our findings demonstrate novel therapeutic targets and treatment strategies for undifferentiated ATC.
Preclinical • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Zelboraf (vemurafenib) • metformin
1m
DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. (PubMed, Pathol Res Pract)
In conclusion, our data identify several tumor entities that can show DOG1 expression levels at similar levels as in GIST. Although DOG1 is tightly linked to a diagnosis of GIST in spindle cell tumors, the differential diagnosis is much broader in DOG1 positive epithelioid neoplasms.
Journal
|
ER (Estrogen receptor)
|
ER expression
1m
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature. (PubMed, ESMO Open)
Therapy with the ALK inhibitor (ALKi) brigatinib led to dramatic and durable disease remission, despite previous disease progression on the ALKi alectinib. This case underscores the potential clinical use of molecular profiling in rare diseases with limited treatment options and suggests that the ALK-R1192P point mutation might predict sensitivity to brigatinib.
Clinical • Review • Journal • Next-generation sequencing
|
ALK (Anaplastic lymphoma kinase)
|
ALK mutation • ALK R1192P
|
Alecensa (alectinib) • Alunbrig (brigatinib)
1m
Inherited/Genetically-Associated Pheochromocytoma/ Paraganglioma Syndromes and COVID-19. (PubMed, Medicina (Kaunas))
Thus, subjects with HIF1α-associated PPG syndromes may benefit from an inherent protective effect against COVID-19. Such an implication of HIF1α vis-à-vis COVID-19 could open ways of therapeutic interventions.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
1m
Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers. (PubMed, Medicina (Kaunas))
To date, there is a large diversity in methodologies used in different studies, frequently leading to contradictory results. To evaluate the true significance of predictive markers, more comparable studies should be conducted.
Review • Journal
|
ER (Estrogen receptor)
|
ER expression
1m
Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors. (PubMed, Front Endocrinol (Lausanne))
These overlapped molecules were mainly involved in metabolism-associated pathways, which means that acetylation-mediated metabolic reprogramming might be the molecular mechanism to affect NF-PitNET invasiveness. This study provided the first acetylomic profiling and acetylation-mediated molecular pathways in human NF-PitNETs, and offered new clues to elucidate the biological functions of protein acetylation in NF-PitNETs and discover novel biomarkers for early diagnosis and targeted therapy of NF-PitNETs.
Journal
|
PGK1 (Phosphoglycerate Kinase 1)
1m
Comprehensive Pan-Cancer Analysis of Heat Shock Protein 110, 90, 70, and 60 Families. (PubMed, Front Mol Biosci)
HSPA2-HSPA7 (r = 0.031, p = 0.009) and HSPA1A-HSPA7 (r = 0.516, p < 0.001) were positive correlation in colon adenocarcinoma. These analysis and validation results show that HSP families play an important role in the occurrence and development of various tumors and are potential tumor diagnostic and prognostic biomarkers as well as anti-cancer therapeutic targets.
Journal • Pan tumor
|
HSPH1 (Heat Shock Protein Family H (Hsp110) Member 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
1m
Long-term follow-up of a case of MEN1 and literature review. (PubMed, Neuro Endocrinol Lett)
MEN1 is an uncommon condition in clinical settings, and it is important that clinicians be made aware of this disorder so that they can provide patients with appropriate and timely treatments.
Clinical • Review • Journal
|
MEN1 (Menin 1)
1m
Clinical Outcomes of Diffuse Sclerosing Variant Papillary Thyroid Carcinoma in Pediatric Patients. (PubMed, Laryngoscope)
Pediatric patients with DSV have more advanced disease at diagnosis and are more likely to experience progression of disease compared to patients with N-PTC. The prevalence of RET fusions in our cohort recapitulates the frequency of this alteration described in prior studies.
Clinical • Clinical data • Journal
|
RET (Ret Proto-Oncogene)
|
RET fusion
1m
Imaging of Pancreatic Neuroendocrine Neoplasms. (PubMed, Int J Environ Res Public Health)
This article reviews the morphological and functional imaging modalities now available and the imaging features of panNENs. Finally, future imaging challenges, such as radiomics analysis, are illustrated.
Review • Journal
|
SSTR (Somatostatin Receptor)
1m
Immunohistochemical expression of chemokine receptor in neuroendocrine neoplasms (CXCR4) of the gastrointestinal tract: a retrospective study of 71 cases. (PubMed, Rom J Morphol Embryol)
The present study highlighted that high CXCR4 expression is associated with high grade and advanced stage GI-NENs, as well as with metastatic cases. In these cases, high CXCR4 expression could serve as an important target for CXCR4 antagonists.
Retrospective data • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 overexpression • CXCL8 expression • CXCR4 expression
1m
Mechanism underlying circularRNA_014301-mediated regulation of neuronal cell inflammation and apoptosis. (PubMed, Exp Ther Med)
By promoting PC12 cell apoptosis under inflammatory conditions, it was indicated that circRNA_014301 may suppress SCI. Therefore, circRNA_014301 may represent a potential target for SCI diagnosis and therapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • BAX (BCL2-associated X protein) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression
1m
Changes of stem cell niche during experimental pituitary tumor development. (PubMed, J Neuroendocrinol)
In conclusion, our data revealed pituitary SC pool fluctuations during hyperplastic/adenomatous development, with differential localization of the SC/TSC niche in this process. These findings may help to provide a better understanding of these cell populations, which is crucial for achieving advancements in the field of pituitary tumor biology.
Journal
|
CD133 • CD44 • SOX2 • SOX9 (SRY-Box Transcription Factor 9) • NES (Nestin)
1m
MiR-222-3p promotes the proliferation, migration and invasion of papillary thyroid carcinoma cells through targeting SLC4A4. (PubMed, Histol Histopathol)
MiR-222-3p can promote the proliferation, migration and invasion of PTC cells through targeting SLC4A4. MiR-222-3p is expected to be a molecular therapeutic target for PTC patients.
Journal
|
SLC4A4 (Solute carrier family 4 member 4)
1m
The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours. (PubMed, J Neuroendocrinol)
NCAM expression does not differ between PitNETs and normal pituitary, and does not appear to relate to tumour invasiveness or proliferation. However, our data suggest a possible role for cytokines in the modulation of NCAM expression in PitNETs, particularly CXCL10, CX3CL1 and FGF-2, but not for immune cell infiltrates.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD163 (CD163 Molecule) • FGF2 (Fibroblast Growth Factor 2) • NCAM1 (Neural cell adhesion molecule 1) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • FOXP3 (Forkhead Box P3)
|
NCAM1 expression • FOXP3 expression
1m
The Clinical Utility of Preoperative Thyroglobulin for Surgical Decision Making in Thyroid Disease. (PubMed, J Surg Res)
Preoperative serum Tg levels were lower in patients with DTC compared to those with benign disease on final pathology and did not correlate with extent of lymph node metastasis in patients with DTC. We found that serum Tg levels obtained in the preoperative setting do not predict DTC or lymph node metastasis and, therefore, do not inform the extent of surgery for differentiated thyroid cancer.
Clinical • Journal
|
TG (Thyroglobulin)
1m
Identification of RET fusions in a Chinese multi-cancer retrospective analysis by next-generation sequencing. (PubMed, Cancer Sci)
Approval of Retevmo (Selpercatinib) for treatment of lung and thyroid cancer with RET gene mutations or fusions, calls for studies to explore RET fusion partners and their eligibility for RET based targeted therapy...Co-occurrence of EGFR mutations and RET fusions with rare partner genes (rather than KIF5B) in LC patients was correlated with EGFR-TKI resistance and may predict response to targeted therapies. Findings from this study provide a guide to clinicians in determining tumors with specific fusion patterns as candidates for RET targeted therapies.
Retrospective data • Journal • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6) • NCOA4 (Nuclear Receptor Coactivator 4) • ERC1 (ELKS/RAB6-Interacting/CAST Family Member 1)
|
EGFR mutation • RET fusion • RET mutation • NCOA4-RET fusion
|
Retevmo (selpercatinib)
1m
SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov)
P3, N=77, Terminated, Ipsen | Completed --> Terminated; National Comprehensive Cancer Network & European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment.
Clinical • Trial termination
|
SSTR (Somatostatin Receptor) • CHGA (Chromogranin A)
|
SSTR positive
|
Somatuline Depot (lanreotide prolonged-release subcutaneous)
1m
Carcinoembryonic Antigen Increase in a Patient with Colon Cancer Who Have Achieved Complete Remission and Negative F-FDG PET/CT: Don't Forget the Thyroid! (PubMed, Curr Oncol)
We performed a F-fluorodihydroxyphenylalanine (F-FDOPA) PET/CT preoperatively which revealed a punctiform focus of the right thyroid lobe corresponding to a pT1aN1aMxR0 medullary thyroid carcinoma, histopathologically confirmed. This case highlights that despite the potential usefulness of F-FDG PET/CT in case of an unknown source of elevated CEA this imaging may be falsely negative as in the case of MTC and should lead to further explorations.
Clinical • Review • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
1m
Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer. (PubMed, Expert Opin Drug Discov)
The approval study ARROW trial showed that patients with RET-mutant medullary thyroid cancer had a better overall response rate to pralsetinib compared to standard-of-care treatments. Additional clinical trials or data enrichment of existing databases are desirable in order to verify and further describe the clinical benefit of pralsetinib in such patients to fully understand its pharmacological profile.
Preclinical • Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
|
Gavreto (pralsetinib)
1m
Utility of droplet digital polymerase chain reaction for TERT and BRAF mutational profiling of thyroid nodules. (PubMed, BMC Cancer)
Combining cytology with ddPCR analysis of BRAFV600E and TERT can improve the diagnostic accuracy of thyroid FNAB, and help predict aggressive pathology.
Journal • Polymerase Chain Reaction
|
BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
|
BRAF V600E • BRAF mutation • BRAF V600 • TERT mutation
1m
Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial. (PubMed, Clin Endocrinol (Oxf))
Our findings indicated that there was no difference in the long-term outcomes with RAI ablation using either 1.1 or 3.7 GBq in patients with low/intermediate risk of recurrence DTC, and 1.1 GBq RAI might be suitable for patients who are recommended for ablation.
Clinical • Journal
|
TG (Thyroglobulin)
|
thyroxine
1m
Triptolide is a Promising Therapeutic Approach in Treating Thyroid Cancer Based on in silico and in vitro Experiment. (PubMed, Drug Des Devel Ther)
We considered that triptolide could treat thyroid cancer by inhibiting cell proliferation, inducing apoptosis and inhibiting inflammatory pathways such as the NF-κB and MAPK signaling pathways. CDKN1A, c-JUN, RELA, and TP53 were involved in the antithyroid cancer mechanism of triptolide.
Preclinical • Journal
|
TP53 (Tumor protein P53) • RELA (RELA Proto-Oncogene) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 expression
|
TriptoSar (triptolide)
1m
Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on Tc-Octreotide and posttherapeutic Lu-DOTA-TATE scans. (PubMed, World J Nucl Med)
Then, the patient underwent two cycles of therapy with Lu-DOTA-TATE, on that the same appearance was observed. The uptake in the tumor thrombus remained somewhat unchanged, but clinically, a significant improvement of the intractable ascites was achieved.
Journal
|
SSTR (Somatostatin Receptor)
|
Lutathera (lutetium Lu 177 dotatate)
1m
Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience. (PubMed, World J Nucl Med)
These findings can help restratify patients for RAI treatment and change patient management in certain cases. Such stratification will ultimately help to optimize successful treatment outcomes and improve patient quality of life.
Clinical • Journal
|
TG (Thyroglobulin)
1m
circ_0067934 promotes the progression of papillary thyroid carcinoma cells through miR-1301-3p/HMGB1 axis. (PubMed, Neoplasma)
In conclusion, our results provided a novel insight into circ_0067934 in the tumorigenesis and progression of PTC. Circ_0067934 might be a prognostic marker or therapeutic target for PTC treatment.
Journal
|
HMGB1 (High Mobility Group Box 1) • MIR1301 (MicroRNA 1301)
1m
Construction and Evaluation of a Tumor Mutation Burden-Related Prognostic Signature for Thyroid Carcinoma. (PubMed, Comput Math Methods Med)
Finally, through Gene Set Enrichment Analysis (GSEA) on high/low-risk groups, DEGs were found to be mainly enriched in signaling pathways related to DNA repair. Overall, based on the TCGA-THCA dataset, we constructed a 5-gene prognostic signature through a trail of bioinformatics analysis.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
|
TMB-H • TMB-L
1m
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. (PubMed, Cancer Med)
Patients who have received PRRT out to 68 months following treatment do not show concerning hypopituitarism although there may be the suggestion of growth hormone deficiency developing. However, hypogonadism is common in men with NETs so the gonadal axis should be assessed in men with suggestive symptoms as the treatment of testosterone deficiency may improve the quality of life.
Journal
|
SSTR (Somatostatin Receptor)
|
SSTR Expression
1m
Clinical • Enrollment open
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Somatuline Depot (lanreotide prolonged-release subcutaneous) • Sandostatin LAR Depot (octreotide acetate) • octreotide chloride FluidCrystal Injection depot (CAM2029)
1m
Endocrine and neuroendocrine tumors (PubMed, Chirurg)
In the case of hereditary diseases (FMTC, MEN2), early prophylactic surgery is often necessary and prevents the occurrence of advanced carcinomas; however, the determination of the extent of resection in follicular lesions or the distinction between noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and follicular variants of papillary thyroid carcinoma can also be determined with the help of specific markers. Overall, molecular pathology has an increasingly more important role in these entities and is also the topic of ongoing research projects.
Review • Journal
|
NF1 (Neurofibromin 1)
|
NF1 mutation
1m
Autophagy-Related Proteins Are Differentially Expressed in Adrenal Cortical Tumor/Pheochromocytoma and Associated with Patient Prognosis. (PubMed, Int J Mol Sci)
Compared to ACT, the proportion of LC3A, LC3B, beclin-1, and LC3B (ISPC) positivity was higher in PCC, whereas p62 positivity was lower. Similarly, p62 positivity in PCC was associated with patient prognosis of OS.
Clinical • Journal
|
BECN1 (Beclin 1)
1m
Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer (clinicaltrials.gov)
P2, N=14, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Slow/Insufficient accrual
Clinical • Trial termination
|
BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • TG (Thyroglobulin)
|
BRAF V600E • BRAF V600 • RET mutation • RET rearrangement
1m
CircRNA NRIP1 promotes papillary thyroid carcinoma progression by sponging mir-195-5p and modulating the P38 MAPK and JAK/STAT pathways. (PubMed, Diagn Pathol)
In conclusion, CircRNA NRIP1 promoted PTC progression by accelerating PTC cells proliferation, invasion and tumor growth, while impeding apoptosis by way of sponging miR-195-5p and regulating the P38 MAPK and JAK/STAT pathways.
Journal
|
JAK2 (Janus kinase 2) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • MIR195 (MicroRNA 195)
1m
Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease. (PubMed, Clin Nucl Med)
We present an unusual case of transiently increased blood pool uptake of 68Ga-DOTATATE in a patient with well-differentiated stage IV neuroendocrine tumor, with Ki-67 <2% (WHO grade 1) maintained on lanreotide. During serial 68Ga-DOTATATE PET/CT examinations, increased blood pool accumulation of presumably unbound 68Ga was demonstrated, which could impact the Kenning score and lead to a false treatment response assessment.
Clinical • Journal
|
SSTR (Somatostatin Receptor)
1m
Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease. (PubMed, Front Endocrinol (Lausanne))
Treatment with everolimus in three patients was not successful, whereas cabozantinib resulted in a disease stabilization in a heavily pretreated patient...PRRT demonstrated promising activity; tyrosine kinase inhibitors warrant further investigations. Further molecular characterization and prospective evaluation of this rare tumor entity are needed.
Clinical • Journal
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
everolimus • Cabometyx (cabozantinib tablet)
1m
Exploring Somatic Alteration Associating With Aggressive Behaviors of Papillary Thyroid Carcinomas by Targeted Sequencing. (PubMed, Front Oncol)
RBL2 was found to be significantly correlated to event-free survival, FOXO1, MUC6, PCDHB9, NOTCH1, FIZ1, and RTN1 were significantly associated with EFS, while BRAF mutant was not correlated to any of the prognosis indicators. Our findings in this study might open more choices when designing thyroid gene panels used in FNA samples to diagnose PTC and predict the potentially aggressive behavior of PTC.
Journal
|
BRAF (B-raf proto-oncogene) • NOTCH1 (Notch 1) • MUC6 (Mucin 6)
|
BRAF mutation
1m
Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer. (PubMed, Acta Biochim Biophys Sin (Shanghai))
Single-sample gene set enrichment analysis showed that high-risk cases exhibit changes in several important tumorigenesis-related pathways, such as the intestinal immune network and the p53 and Hedgehog signaling pathways. Our results indicate that lipid metabolism-related gene profiling represents a potential marker for prognosis and treatment decisions for PTC patients.
Journal
|
PDZK1IP1 (PDZK1 interacting protein 1)
1m
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. (PubMed, Expert Opin Investig Drugs)
Endocrine therapies include tamoxifen, a selective estrogen receptor modulator (SERM), that exhibits receptor agonist and antagonist activity, and aromatase inhibitors that block estrogen biosynthesis but which demonstrate acquired resistance. Fulvestrant, the only currently approved SERD, is limited by poor drug-like properties...Using PubMed, clinicaltrials.gov, and congress websites, this review explored the preclinical development and clinical pharmacokinetics from early phase clinical studies (2015 or later) of novel oral SERDs, including giredestrant, amcenestrant, camizestrant, elacestrant, and rintodestrant...Through property- and structure-based drug design of estrogen receptor-binding, antagonism, degradation, anti-proliferation, and pharmacokinetic properties, these SERDs have distinct profiles which impact clinical dosing, efficacy, and safety. Assuming preliminary safety and activity data are confirmed in phase 3 trials, these promising agents could further improve the management, outcomes, and quality of life in HR-positive breast cancer.
Journal
|
ER (Estrogen receptor)
|
HR positive
|
tamoxifen • fulvestrant • amcenestrant (SAR439859) • giredestrant (GDC-9545) • elacestrant (RAD1901) • camizestrant (AZD9833) • rintodestrant (G1T48)
1m
The 2021 World Health Organization Classification of Tumors of the Thymus and Mediastinum: What's new in thymic epithelial, germ cell and mesenchymal tumors? (PubMed, J Thorac Oncol)
Endowed with updated clinical information and state-of-the-art PET/CT images, the 5 edition of the WHO classification of TETs, GCTs and mesenchymal neoplasms with its wealth of new diagnostic and molecular insights will be a valuable source for pathologists, radiologists, surgeons and oncologists alike. Therapeutic perspectives and research challenges will be addressed as well.
Review • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
TMB-L
1m
Lipoxin A methyl ester protects PC12 cells from ketamine-induced neurotoxicity via the miR-22/BAG5 pathway. (PubMed, Hum Exp Toxicol)
LXA ME can protect PC12 cells from ketamine-induced neurotoxicity by activating the miR-22/BAG5 signaling pathway. Thus, LXA ME can be used as a protective drug against ketamine-induced neural damage.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAG1 (BAG Cochaperone 1)
|
BCL2 expression
|
ketamine
1m
BRD3-NUTM1-expressing NUT carcinoma of lung on endobronchial ultrasound-guided transbronchial needle aspiration cytology, a diagnostic pitfall. (PubMed, Diagn Cytopathol)
When a specimen demonstrates a dual cell population of squamoid cells and primitive-looking tumor cells in the wrong clinical context (i.e., young patient with no smoking history), further molecular profiling is warranted to include the differential of a primary NC of the lung. The cytological features of NC itself have rarely been documented and moreover, that of a primary NC of the lung with BRD3-NUTM1 fusion has never been reported. We herein report cytological findings of a primary NC of the lung with BRD3-NUTM1 fusion gene.
Journal • Endobronchial ultrasound
|
NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • BRD4 (Bromodomain Containing 4) • TP63 (Tumor protein 63) • NUTM1 (NUT Midline Carcinoma Family Member 1)
1m
An aggressive poorly differentiated plurihormonal Pit-1-positive adenoma. (PubMed, Endocrinol Diabetes Metab Case Rep)
Temozolomide is first-line chemotherapy for aggressive pituitary tumours and carcinomas. Further development of novel targeted therapies, such as peptide receptor radionuclide therapy (PRRT), vascular endothelial growth factor (VEGF) receptor-targeted therapy, tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and immune checkpoint inhibitors, is needed.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR Expression • SSTR2 positive
|
temozolomide
1m
In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma. (PubMed, Int J Cancer)
A relatively high frequency of pRb inactivation was observed in both LCNEC- and ADC-parts, suggesting an underlying role in LCNEC-ADC development. Furthermore, neuroendocrine differentiation might be modulated by Ascl1(+) and Rest(-) expression.
Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1)
|
TP53 mutation • KRAS mutation • STK11 mutation • KEAP1 mutation
1m
Comparison of clinical characteristics between sporadic gastrinoma and multiple endocrine neoplasia type 1-related gastrinoma (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
The 5-year survival rate of patients with and without liver metastasis was 76.2% vs. 100%, respectively (P=0.061). Compared with sporadic gastrinoma, MEN1-related gastrinoma has longer diagnosis delay, smaller tumor diameter, lower tumor grading, lower risk of liver metastasis, and is more likely to complicate with type 2 g-NET, while there is no difference in survival between the two tumor types.
Clinical • Journal
|
GAST (Gastrin 2) • MEN1 (Menin 1)
1m
Advances in immunotherapy for neuroendocrine neoplasms (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
Studies have shown that the efficacy of immune monotherapy in NEN is limited, and it can be considered for selected patients. Biomarkers for predicting efficacy of immunotherapy include PD-L1 expression, TMB-H, MSI-H/dMMR, etc. Combined regimens of anti-CTLA-4 and anti-PD-1/PD-L1 inhibitors, and immune checkpoint inhibitor combined with anti-angiogenic drugs or chemotherapy are promising in patients with NEN, and it is worthwhile to further explore of the responding populations.
Journal • Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
PD-L1 expression • TMB-H • MSI-H/dMMR • TMB-L + PD-L1 expression
1m
Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium. (PubMed, Oncogene)
However, cell of origin influenced disease latency, metastatic potential, and the transcriptional profile of the SCLC phenotype. Together this reveals that MYC overexpression alone provides a proliferative advantage but when combined with deletion of Trp53 and Rb1 it facilitates the formation of aggressive SCLC from multiple cell lineages.
Journal
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1)
|
TP53 mutation • MYC amplification • RB1 mutation • MYC overexpression • MYC expression • RB1 deletion • TP53 expression • RB1 mutation + TP53 mutation • RB1 overexpression
1m
Previous Extrapulmonary Malignancies Impact Outcomes in Patients With Surgically Resected Lung Cancer. (PubMed, Front Surg)
Although overall survival was lower in patients with previous extrapulmonary malignancies, previous breast or thyroid cancer did not increase mortality. Our findings may help surgeons to predict prognosis in this subgroup of patients with primary lung cancer.
Clinical • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
1m
Extracellular Matrix in Synthetic Hydrogel-based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 inhibitors. (PubMed, Adv Mater)
Finally, we demonstrate that therapeutic response in CRPC-NEPCs under drug-resistant ECM conditions can be overcome by first cellular reprogramming with EZH2 inhibitors, followed by DRD2 treatment. The synthetic hydrogel-based organoids suggest the regulatory role ECM may play in therapeutic response to targeted therapies in CRPC-NEPCs and enable the discovery of single drugs and combination therapies to overcome resistance.
Journal
|
DRD2 (Dopamine Receptor D2)
1m
Medullary thyroid cancer and pheochromocytoma in MEN2A: are there parent of origin effects on disease expression? (PubMed, Fam Cancer)
There was also a slight deficit of male offspring: 1.1 sons each per affected mother and father vs. 1.2 daughters per affected mother and 1.4 daughters per affected father. These data suggest a parent-of-origin effect in MEN2A, warranting international collaborative research.
Journal
|
RET (Ret Proto-Oncogene)